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This dissertation focuses on applying covalent labeling (CL) and mass 
spectrometry (MS) for characterizing protein-ligand complexes. Understanding protein-
ligand interactions has both fundamental and applied significance. Covalent labeling is a 
protein surface modification technique that selectively modifies solvent-exposed amino 
acid side chains of proteins. A covalent bond is formed between the functional groups of 
labeling reagent and protein’s side chain. One of the key factors that affects CL reactivity 
is a side chain’s solvent accessibility. Ligand binding protects residues on the protein 
surface from being labeled, and residues involved in ligand binding can be indicated via 
decreases in labeling extents. 
The main goal of this study is to develop strategies that apply CL-MS to 
characterize protein-ligand complexes. Diethyl pyrocarbonate (DEPC) is the labeling 
reagent we focused on. First, we developed a strategy that can identify ligand binding site 
as well as determine the ligand binding affinity to the protein. We characterized the 
complexes between β-2 microglobulin (β2m) and three amyloid inhibiting molecules 
under Cu(II)-induced amyloid forming conditions. The rest of the dissertation focused on 
comparing the information from two complementary MS-based methods, hydrogen 
deuterium exchange (HDX)-MS and CL-MS. Using three model protein-ligand systems, 
we demonstrate that the two labeling techniques can provide synergistic structural 
information about protein-ligand binding when reagents like DEPC are used for CL 
because of the differences in the intrinsic reaction rates of DEPC-based CL and HDX.  
This dissertation highlights the power of CL-MS for characterizing protein-ligand 
complexes. The understanding of how three amyloid inhibiting molecules bind to Cu(II)-
β2M could facilitate future library screening for new drug candidates. Our work also 
vi 
indicates CL-MS is capable of characterizing protein-ligand complexes that are difficult 
to study by other methods such as X-ray crystallography and nuclear magnetic resonance 
spectroscopy. 
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CHAPTER 1 
 
INTRODUCTION 
1.1 Mass Spectrometry for Characterizing Protein-Ligand Complexes 
Protein-ligand interactions, a type of molecular recognition process, are 
fundamental in all living organisms. Understanding the mechanisms of protein-ligand 
interactions is an integral step to understanding biology at molecular level [1]. For drug 
discovery, design, and development purpose, intensive characterizations of the protein-
ligand complexes of interest is also essential for the pharmaceutical industry [2]. With all 
these purposes, various kinds of analytical methods have been developed to study 
different aspects of the protein-ligand interactions, such as ligand binding affinity of the 
protein, ligand binding site of the protein, and whether ligand binding will induce 
structural changes to the protein. In this work, we aimed to achieve the residue-level 
structural information of the protein-ligand complexes, and mass spectrometry (MS) 
based methods were chosen as methods of choice to study.  
Mass spectrometry (MS) is an analytical technique that measures mass-to-charge 
ratios (m/z) of gas-phase ions. In one way, analyte in solution phase can be ionized by an 
ion source to generate gas-phase chemical species, and a mass analyzer sorts the ions into 
a spectrum based on their m/z values [3]. However, as its name indicated, MS reports 
only “mass”, as indicated by m/z of the analyte, it does not readily gives us the “picture”, 
i.e. structural analysis of the protein-ligand complex. Thus, some other techniques are 
required to work together with MS that the structural information can be encoded and 
delivered. These MS-based structural methods do not require the crystal of the protein-
ligand complex be available, nor are they limited by the size of the protein. These 
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features make them possible to serve as an alternative when other well-established 
methods such as X-ray crystallography or nuclear magnetic resonance (NMR) are not 
applicable [4, 5]. 
1.2 Covalent Labeling-Mass Spectrometry for Characterizing Protein-Ligand 
Complexes 
1.2.1 Covalent Labeling-Mass Spectrometry 
The MS-based method that we focused on in this thesis is covalent labeling-mass 
spectrometry (CL-MS). Covalent labeling (CL) is a protein surface modification 
technique that selectively modifies solvent-exposed amino acid side chain of the protein, 
a covalent bond will be formed between the functional groups of labeling reagent and 
protein’s side chain which can encode the structural information around the certain side 
chain, e.g. topology, solvent accessibility, and microenvironment. The label will cause a 
mass shift compared to the unmodified side chain such that a modification could be 
identified by MS, which complete the method as CL-MS [6, 7].  
There have been many CL techniques being developed and they can be divided 
into two categories: (a) amino acid specific labeling techniques (e.g. Lys-specific 
labeling, Trp-specific labeling, carboxylic acid labeling) [6] and (b) non-specific labeling 
techniques (e.g. hydroxyl radical footprinting [8] and DEPC labeling [7]). In the work 
presented in this thesis, the most applied CL technique is DEPC labeling, although some 
other kinds of amino acid specific labeling reagents were also applied. 
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1.2.2 Diethyl pyrocarbonate  
Diethyl pyrocarbonate (DEPC) is a commercially available labeling reagent that 
can react with a range of nucleophilic residues: Cys, His, Lys, Thr, Tyr, Ser, and N-
termini via nucleophilic substitution reactions (Figure 1.1). Comparing to some other 
non-specific labeling techniques, DEPC is capable of modifying few types of amino 
acids. For example, fast photochemical oxidation of proteins (FPOP) can modify at least 
14 kinds of common amino acid residues [8, 9], and some more recently developed 
labeling reagent such as •CF3 can modify 18 kinds of residues [10]. However, being able 
to modify up to 6 kinds of residues allows DEPC to cover about up to 25% sequence in a 
typical protein, which is rather informative. Also, the corresponding data interpretation of 
DEPC is considerably easier. DEPC labeling will only generate a single type of product, 
which corresponds to a mass shift of +72.021 Da. This greatly simplifies the 
identification of labeled sites. Manual data interpretation is rather easy as shown in the 
work for Chapter 2 and 3. Although a customized data processing software for DEPC is 
also available [11, 12], which has been applied in the work for Chapter 4. While for some 
non-specific labeling reactions, especially hydroxyl radical based, the reaction could lead 
to multiple kinds of products [8, 9]. This makes the data interpretation of these reactions 
impossible to be derived manually in reasonable time [13, 14].  
DEPC labeling reaction is also very easy to perform. DEPC will directly label the 
protein when being added to the solution that no sophisticated equipment (e.g. laser or 
flow cell) is required at all. While to generate hydroxyl radicals [15], carbenes [16, 17], 
or •CF3[10], a laser is mandatory in most cases. A laser source is usually expensive, and 
lasers can potentially be dangerous. Besides this, majority of these reactions also require 
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both precise and continuous reaction time control that a set of specialized experimental 
setup (usually a flow cell) must be accompanied. All these restrictions cause radical 
based reactions to only be performed by a well experienced experimenter. For DEPC 
labeling, the requirement for performer’s experience or equipment is minimum. 
Besides the differences described above, the most distinctive difference between 
DEPC labeling and other popular non-specific labeling reactions is the intrinsic reaction 
rate. The intrinsic reaction rate for DEPC is about tens of seconds [18], while hydroxyl 
radicals [15, 19, 20], carbenes [16, 17], or •CF3 [10] all have much faster reaction rate 
range from nanoseconds to microseconds, which is comparable to or faster than protein 
folding rates. This difference makes DEPC (and CL reactions which have similar reaction 
rate) more likely to adopt a different strategy from those extremely fast labeling reactions 
when being applied to characterize protein-ligand complexes. For example, Gross and co-
workers have developed a set of strategies applying FPOP for characterizing protein-
ligand complexes and protein’s higher order structures (HOS) [21]. When being applied 
to determine the ligand binding affinity to the protein, due to hydroxyl radical’s 
extremely fast reaction speed, the strategy was developed based on monitoring protein’s 
dynamic changes induced by ligand binding [22, 23]. While for DEPC, the reaction is too 
slow to monitor protein’s dynamic change, also the competition between labeling 
reaction and ligand’s kon/koff must be considered, that a different strategy monitoring the 
fraction of ligand free protein in the system was developed (Chapter 3). Another example 
is, when being used as a complementary method of hydrogen-deuterium exchange (HDX) 
MS for characterizing protein-protein interactions, FPOP is considered able to provide 
more information of subtle differences in conformation or dynamics, when the exchange 
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at the local region is too rapid to the HDX time scale [24]. While for DEPC, again, we 
propose DEPC is too slow to indicate rapid changes in dynamics of the protein, that the 
result of DEPC labeling will be more focusing on the overall decrease in solvent 
accessibly of ligand binding region (Chapter 4). The reader should keep in mind that this 
thesis will only focus on CL reactions whose intrinsic reaction rate are about tens of 
seconds. 
 
Figure 1.1 Modification reaction of DEPC labeling. 
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Our lab has been developing the strategies using DEPC as a CL reagent over a 
decade and the technique has been improved along with the studies. The first work using 
DEPC for protein surface mapping was reported in 2008 [25]. In this work, the basic 
strategy of applying this CL reagent was developed, with the understanding of second-
order reaction between DEPC and proteins, an estimation of intrinsic reaction rates, as 
well as the discovery that multiple kinds of residues can be modified. Following this first 
work, to maximize the resolution of DEPC as a labeling reagent for CL-MS, Zhou et al. 
optimized the “bottom-up” CL-MS strategy (Section 1.2.5) for DEPC labeled proteins. In 
the first set of studies, the lability of modified residues through the protein denaturing and 
digesting process was investigated. Besides the observation that the labels are 
considerably labile, label scrambling to Cys could happen if free Cys residues are not 
alkylated [26]. Also, minimizing the time between the labeling reaction and MS 
measurements could avoid label loss, preserve the information encoded by CL, and 
increase the acquired protein structural resolution [27]. In another set of studies, tandem 
MS methods that are suitable for the DEPC labeled peptides were discussed. This work 
suggests scrambling during tandem MS fragmentation can be minimized if using electron 
transfer dissociation instead of collision-induced dissociation if used [28]. In the latest 
studies, Limpikirati and coworkers explored the effect from microenvironment to the 
DEPC labeling and found microenvironment in the intact protein tuned weakly 
nucleophilic side chains (Ser, Thr, and Tyr) so that they can be effectively modified, 
while the ones from unstructured peptides only have limited or no reactivity [29]. Also, 
the study of correlating DEPC labeling results with SASA at each modified residue is still 
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going on, which is expected to be utilized for model protein complex structures in the 
near future. 
For application and related method developments, DEPC labeling was first 
applied to resolve the Cu(II) involved β-2-microglobulin (β2m) amyloid forming 
pathway (see Section 1.4). This part of work includes development of a set of strategies 
using CL-MS to assess the structure of Cu(II)-β2m monomer [30] and investigate the 
structure of β2m dimer [31] and tetramer [32] formed in the Cu(II) involved amyloid 
forming pathway. In more recent studies, DEPC is further applied for characterizing 
therapeutic proteins. Different from previous works that also characterize protein 
complexes, therapeutic proteins are especially challenging due to their size and 
complexity.  Borotto et al. and Limpikirati et al. demonstrated that DEPC labeling can 
identify specific protein regions that mediate aggregation and regions that undergo subtle 
conformational changes upon mishandling of these proteins [11, 12]. Importantly, DEPC 
labeling provides excellent structural resolution (up to 30% of the surface residues) that 
allows probing subtle conformation changes that are not detectable by common 
biophysical techniques [12]. 
1.2.3 Other Amino Acid Specific Labeling Reagents 
In this study, other kinds of amino acid specific labeling reagents were also 
applied: 1) 2,3-butanedione (BD) that selectively modifies arginine [33], 2) 1-ethyl-3-(3-
dimethylaminopropyl)carbodiimide and glycine ethyl ester (EDC-GEE) labeling pair that 
selectively modifies aspartic acid and glutamic acid [34], 3) Dimethyl(2-hydroxy-5-
nitrobenzyl)sulfonium bromide (HNSB) that selectively modifies tryptophan [35]. 
(Shown in Figure 1.2)  
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These amino acid specific labeling reactions have intrinsic reaction rates in the 
same range as DEPC, so they can be applied with the same strategy as DEPC for 
characterizing protein-ligand complexes. In some cases, an amino acid specific labeling 
reaction serve as the main labeling methods when ligand binding information is not 
available by DEPC. Otherwise, these techniques were used to improve the overall 
confidence of the CL-MS result by combining the information with that of DEPC. 
 
 
Figure 1.2 Amino acid specific labeling reagents. 
 
1.2.4 The Basic Idea of CL-MS for Characterizing Protein-Ligand Complexes 
Protein-ligand interactions are primarily mediated by non-covalent interactions, 
e.g. hydrogen bonds or van der Waals interactions between ligand’s functional group and 
amino acid side chains. Besides these interactions, ligand binding can also protect the 
involved region of the protein’s surface. As a result, protein-ligand interactions can lead 
to a decrease in solvent accessibility of the side chains involved in ligand binding. 
Because side chain’s solvent accessibility is one of the key factors that affect CL 
reactivity [7]. In its most straightforward implementation, ligand binding protects 
residues on the protein surface from being labeled. This idea is the main concept that we 
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can apply CL-MS to characterize protein-ligand complexes and will be discussed and 
demonstrated through the entire thesis. When using CL-MS to identify the ligand binding 
site, the residues involved in ligand binding are indicated via decreases in labeling extents 
(summarized by Figure 1.3). When using the labeling ratio of specific residues in the 
protein to indicate the fraction of ligand-free protein in the system, ligand binding affinity 
can be determined. As prior to the point that the binding site is fully occupied by the 
increasing concentration of the ligand, the lower the ligand-free fraction is, the smaller 
the labeling extent is. Additionally, a significant change of residue’s solvent accessibility 
might also be caused by major conformational changes of the protein upon ligand binding 
in some cases. CL-MS is also capable to report such conformational changes by changes 
in labeling extents.  
 
 
Figure 1.3 Idea of applying CL-MS for characterizing protein-ligand complexes. 
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1.2.5 Experiment Design and Workflow 
 
Figure 1.4 Experiment workflow for CL-MS to characterizing protein-ligand 
complexes. 
 
During CL experiments, the solvent exposed residues can be modified, thus 
providing indirect structural information. While the buried residues should be 
unmodified. As illustrated in Figure 1.3, ligand binding information obtained from a CL 
experiment comes from comparing the labeling ratio of the protein reacted under at least 
two conditions: usually, it is with and without ligand conditions. The resulting differential 
reactivity is used to deduce ligand binding information. Besides following the basic 
principle of CL experimental design that the labeling reagent must be used in a way that 
will not perturb protein’s HOS to avoid any change to the protein during labeling, the 
amount of ligand being applied is also critical when designing a set of experiments to 
characterize protein-ligand complexes. Ideally, to ensure optimal sensitivity for detecting 
changes in labeling, maximum protein occupancy is desired. Usually, this can be easily 
achieved when the dissociation constant or related physiological study has been 
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performed that a valid range of ligand concentration is known. However, for the less 
characterized protein or complex, optimizing ligand concentrations and allowing proper 
time for complex formation should be implied. The caveat is that protein aggregation 
might occur in some circumstances, given improper conditions being used. When this is 
the case, the false-positive ligand binding site will be reported, which could be burial 
resulting from protein-protein interactions, but not protein-ligand binding. Such a kind of 
problem was frequently encountered in experiments involving amyloid forming protein 
β-2-microglobulin, as described in Chapter 2 and 3.  
After the labeling reaction being performed and quenched, the labeled protein 
sample can be directly analyzed by MS or LC–MS to get information at a global level. 
Otherwise, a bottom-up proteomic method can be applied. In the bottom-up approach, the 
labeled protein is proteolytically digested prior to LC–MS/MS analysis (Figure1.4). 
Besides CL-MS experiments require complete or nearly complete protein sequence 
coverage to obtain the desired structural information, the residue-level spatial resolution 
is also desired. Comparing to top-down sequencing [36-38], bottom-up sequencing [36, 
39, 40] is easier to achieve high spatial resolution as MS/MS is more effective on smaller 
peptides. Usually, labeled sites are pinpointed down to 1 or 2 amino acids, meaning 
ligand binding site can be identified by this technique at residue-level resolution. 
Moreover, modification extents can usually be determined as low as 0.1% or even lower, 
allowing CL modified residues to be detected at good sensitivity. Although bottom-up 
sequencing of covalently labeled proteins still suffers from the usual challenges 
associated with this method, such as biases associated with proteolytic cleavages and 
peptides going undetected during LC/MS experiments.  
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Another important note is, unless being corrected by additional strategy (e.g. 
using internal standard calibration), MS acquired labeling extent is only semi-quantitative 
and not absolute quantitation. This is mainly due to the fact that modified and unmodified 
species have different ionization efficiencies, and they are eluted at the different retention 
times at which the mobile phase composition are also different. When applying CL-MS 
for characterizing protein-ligand complex is often a comparison of labeling extent 
between two conditions (e.g. with and without ligand), absolute labeling extent is not 
necessarily required.  
1.3 Synergistic Information from HDX-MS and CL-MS for Characterizing Protein-
Ligand Complexes 
 
Figure 1.5 Basic idea of applying HDX-MS for characterizing protein-ligand 
complexes. 
 
Hydrogen deuterium exchange (HDX) MS is a well-established method to study 
protein’s HOS used often in the pharmaceutical industry [41-43]. HDX relies on changes 
in mass resulting from amide hydrogen exchange with deuterium solvent. In a commonly 
applied time-course HDX experiment, the reaction can be easily started by dilute protein 
into high percent D2O. After a certain exchanging time, the reaction will be quenched by 
lowering both pH and temperature at which the exchanging rate of amide hydrogen is 
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minimal. Then, the deuterium-labeled protein will be digested by proteolysis and 
analyzed by LC-MS. The acquired information is the deuterium uptake value of a 
peptide/residue at different deuterium exchange time period [44, 45]. These values can be 
further processed and used to characterize protein HOS, protein folding [46-48], and 
protein aggregation kinetics [49]. 
Deuterium exchange rates vary based on a number of factors including protein 
secondary structure, solvent accessibility, pH, and temperature. For an unstructured 
backbone amide hydrogen under neutral pH, the intrinsic exchange rate is on the order of 
milliseconds [50]. However, in a folded protein this exchange rate can vary significantly 
from minutes to days as a result of the sequence structure of the protein, the accessibility 
to solvent and the dynamics of the local region [51]. Upon ligand binding, usually, it is 
expected that local region will has both decreased accessibility to solvent and dynamics 
[52, 53]. As a result of these expected decreases, HDX can be applied to characterize the 
protein-ligand complex [54-56] (see Figure 1.5). 
However, because HDX responds to changes in both solvent accessibility and 
structural fluctuations, it sometimes provides ambiguous information with regard to 
ligand binding site. Information from CL-MS might be applied to help distinguish what 
acquired by HDX. The difference in intrinsic reaction rates between slow covalent 
labeling techniques like DEPC labeling and HDX are 2-3 orders of magnitude. Such a 
slow reaction rate of DEPC allows it to be transparent to cases which solvent exposed 
states of the region are too short-lived to be labeled. While HDX is sensitive to these 
changes because the H to D exchange reaction is orders of magnitude faster. For ligand 
binding regions, decreases in solvent accessibility will be identified by both methods. 
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Thus, when used together, HDX and CL have the potential to provide clearer information 
about protein-ligand binding sites and binding-induced stabilization. 
1.4 β-2-microglobulin and its amyloid inhibiting molecules 
1.4.1 β-2-microglobulin and its Cu(II) induced amyloid forming pathway  
β-2-microglobulin (β2m) is a component of the major histocompatibility complex 
(MHC) class I molecules which presents on all nucleated cells (excludes red blood cells) 
[57]. It is a 99-residue protein composed of seven strands arranged in an anti-parallel 
sandwich motif held together by a lone disulfide bond [58]. Despite its common existence 
in human physiology, for patients on long-term hemodialysis the protein can aggregate 
into amyloid fibers, deposit in joint spaces and eventually lead to deconstruction of the 
joints. This disease is known as dialysis-related amyloidosis (DRA) [59], a kind of 
amyloid diseases. Like many other kinds of amyloid diseases, namely Alzheimer’s and 
Parkinson’s [60-62], β2m amyloid formation process in vivo is not fully understood yet. 
In vitro, several conditions can convert the protein from soluble to insoluble amyloids: 
low pH condition, co-incubation with a truncated version of β2m, trifluoroethanol (TFE), 
thermal denaturation, sonicating the protein with sodium dodecyl sulfate [63-66], and 
incubation with catalytic amounts of Cu(II) [30, 67-72]. The strategy to induce amyloid 
formation that our group applies most is the Cu(II) binding induced strategy, which is 
summarized in Figure 1.6 [30]. Cu(II) concentrations in dialysis patients are higher than 
normal [67], suggesting a molecular role for Cu(II). In addition, the binding of Cu(II) is 
specific at the N-terminus, Ile1-Gln2, His31, and Asp59 of the protein [68, 72] with a 
binding constant of approximately 2 µM. Cu(II) binding will induce some side chain 
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arrangement of the protein monomer, which facilitates the oligomer forming process [71, 
73, 74]. Although a detailed structure of Cu(II)-β2m is not available, the β2m dimer [31] 
and tetramer [32] structures in this pathway have also been characterized in our group’s 
previous study using CL-MS (Figure 1.7). Similar to the idea of using CL-MS for 
characterizing protein-ligand complexes as explained in Section 1.2.4, characterizing the 
structure of protein-protein complexes also relies on decreased labeling ratio caused by 
decreased SASA of certain residues. Decreases in SASA of these residues are caused by 
the protein-protein interactions, i.e. another protein. For example, comparing the labeling 
ratio of a residue from the β2m monomer and the dimer, a residue within the dimer 
interface is expected to have a significantly decreased labeling ratio, while a residue not 
involved in the interface should remain unchanged.   
1.4.2 Amyloid Inhibiting Molecules for Cu(II)-β2m 
Currently, there is no treatment for DRA [75, 76]. Among the efforts to develop 
future drugs targeting DRA, several amyloid formation inhibiting molecules have been 
discovered in vitro [77-83]. Some of them are currently studied under Cu(II) involved 
amyloid forming conditions by our lab: doxycycline, rifamycin SV [77] (Chapter 2) and 
epigallocatechin gallate [78] (Chapter 3) (Figure 1.8). Briefly, these three amyloid 
inhibiting molecules work in a way that redirects the amyloid forming process to form 
dissolvable amorphous aggregates [77, 78] (Figure 1.8). Although it is still arguable if the 
β2m amorphous aggregates are noncytotoxic, some basic understanding of the complex 
formed by Cu(II)-β2m and these amyloid inhibiting molecules would still facilitate drug 
design in the future. 
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In the work presented in this thesis, we investigated the binding site of the 
inhibitor on the Cu(II)-β2m monomer. Some previous work by our group indicates such 
protein-ligand complex exists when inhibitor is involved in the Cu(II) induced amyloid 
formation process [77, 78]. As a follow-up step, we identified the ligand binding site on 
the protein and shed light on the mechanism of these inhibitors. The key challenge to 
experimentally identify the binding site on β2m, or any amyloid-forming protein, was 
how rapidly the monomeric protein could convert to oligomers and aggregates. This 
feature of amyloid forming protein makes conventional protein structural analysis 
techniques, such as X-ray crystallography and NMR, unsuitable. Because CL reaction 
can be completed within minutes, with all the structural information encoded, this time 
scale appears to be suitable for providing protein−ligand binding information for systems 
that are difficult to study by other methods. 
 
Figure 1.6 Summary of Cu(II) induced β2m amyloid formation process. 
TEM figure from [77]. 
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Figure 1.7 Structure of dimer and tetramer in the proposed Cu(II) induced β2m 
amyloid formation process. 
 
Figure 1.8 Amyloid inhibiting molecules for Cu(II)-β2m and example TEM figure of 
amorphous aggregates comparing to β2m fibril. 
TEM figure from [77]. 
1.5 Summary 
Characterizing protein-ligand complexes facilitate both scientific significance and 
practical applications in drug discovery. In this thesis, we developed a set of methods that 
rely on CL-MS to characterize protein-ligand complexes. Ligand binding sites on 
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proteins, ligand binding affinity of the protein, and whether ligand binding will induce 
structural changes to the protein can all be determined by the CL-MS based methods. In 
addition, we also discussed and compared the information of two MS-based methods, 
CL-MS and HDX-MS, to characterize the same protein ligand complexes.  
In Chapter 2, we applied CL-MS to identify the protein binding sites of amyloid 
inhibiting molecules. We show that CL appears to be suitable for providing protein ligand 
binding information for systems that are difficult to study by other methods. 
In Chapter 3, the development of a strategy that uses CL-MS in a ligand-based 
titration to determine the dissociation constant of ligand to protein is described.  
In Chapter 4, we investigated three model systems and demonstrated the 
synergistic structural information available from CL and HDX-MS for characterizing 
protein-ligand interactions. 
Finally, conclusions and future directions of this work are included in Chapter 5. 
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CHAPTER 2 
 
USING CL-MS TO IDENTIFY PROTEIN BINDING SITS OF AMYLOID 
INHIBITING MOLECULES 
 
The work described in this chapter has been published as:  
Liu, T., Marcinko, T. M., Kiefer, P. A., & Vachet, R. W. (2017). Using covalent labeling 
and mass spectrometry to study protein binding sites of amyloid inhibiting molecules. 
Analytical Chemistry, 89(21), 11583-11591.  
 
M.T.M. conducted circular dichroism spectroscopy and fluorescence spectroscopy 
experiments; K.P.A. conducted most ESI-MS titration experiments; L.T. conducted all the 
rest experiments. 
2.1 Introduction 
Amyloid diseases, such as Alzheimer’s and Parkinson’s, are characterized by the 
accumulation of insoluble aggregated proteins in cells, tissues, and organs [1]. Dialysis-
related amyloidosis (DRA) [2], which occurs in patients undergoing long-term 
hemodialysis due to renal dysfunction, involves amyloid deposits of the protein β-2-
microglobulin (β2m) in the musculoskeletal system [3-5]. Currently, there is no treatment 
for DRA [6, 7], but recent in vitro studies have identified several molecules that can 
redirect β2m amyloid formation, suggesting that these molecules might act as prototypes 
for future drug design [8-10]. To facilitate drug design efforts, it would be valuable to 
identify where these molecules bind on β2m, so that targeted screening of compound 
libraries could be conducted to find even more potent molecules. A key challenge to 
experimentally identifying the binding site on β2m, or any amyloid-forming protein, is 
how rapidly the monomeric protein is converted to oligomers and aggregates, which 
makes traditional protein structural analysis techniques, such as X-ray crystallography 
and NMR, unsuitable. To address this challenge, we are exploring methods based on 
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covalent labeling and mass spectrometry (MS) to rapidly map binding sites before 
aggregation occurs.   
Covalent labeling is a protein surface modification technique that relies on 
selective [11] (e.g. succinimides) or non-selective [12-18] (e.g. hydroxyl radicals) 
labeling reagents to covalently modify solvent-exposed amino acid side chains that can 
then be identified by MS and tandem MS, often in conjunction with bottom-up 
sequencing. Covalent labeling approaches can be particularly valuable for finding 
protein-protein or protein-ligand binding sites, as they probe changes in side chain 
solvent accessibility. Our group has found that diethylpyrocarbonate (DEPC) is a 
valuable pseudo-selective reagent for studying protein/protein interactions [19-25]. 
DEPC has some advantages over other non-selective reagents, such as hydroxyl radicals, 
in that it requires no special equipment (e.g. laser or synchrotron), and it results in only a 
single reaction product, thereby simplifying MS analyses and improving detection 
sensitivity. DEPC provides good structural coverage as it can react with up to 30% of the 
residues in the average protein, providing an effective resolution around 8-10 Å [23]. 
While this level of structural detail can often help define protein-protein interaction sites, 
this level of resolution may not be sufficient for identifying small molecule binding sites. 
Consequently, we are exploring the combination of information obtained from DEPC 
labeling with information from other labeling reagents. In this study, we show that other 
labeling reagents, namely 2,3-butanedione (BD), which labels Arg residues [26], and the 
1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC)-glycine ethyl ester (GEE) pair, 
which labels Asp and Glu residues [27], can be used with DEPC to better pinpoint 
protein-small molecule binding sites. To demonstrate the effectiveness of this combined 
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labeling approach, we determine the binding sites of three small molecules known to bind 
to β2m-doxycycline [8], rifamycin SV [9], and suramin [28]. The former two molecules 
are known to inhibit Cu(II)-induced β2m amyloid formation [29, 30] by diverting the 
reaction toward amorphous aggregates, while suramin has no effect on the amyloid 
formation reaction [10]. The identified binding sites are consistent with computational 
modeling and previous biochemical studies, providing validation of the obtained labeling 
results. We predict that our combined labeling approach should be applicable to other 
protein-ligand systems that are difficult to study by more traditional methods. 
2.2 Experimental and Methods 
2.2.1 Materials 
Human full-length β2m was obtained from Lee Biosolutions (Maryland Heights, 
MO). Diethylpyrocarbonate (DEPC), doxycycline hyclate, glycine ethyl ester 
hydrochloride (GEE), imidazole, iodoacetamide, MOPS, MOPS sodium salt, rifamycin 
SV sodium salt, suramin sodium salt, 2,3-butanedione (BD), tris(2-
carboxyethyl)phosphine (TCEP), urea, N-(3-dimethylaminopropyl)-N’-ethylcarbodiimide 
hydrochloride (EDC), and L-arginine were obtained from Sigma-Aldrich (St. Louis, 
MO). Immobilized trypsin and chymotrypsin and triethylamine acetate (pH 8.0, 1 M) 
were obtained from Princeton Separations (Adelphia, NJ). Acetonitrile, ammonium 
acetate, CuSO4, formic acid, potassium acetate, and HPLC grade water were all 
purchased from Fisher Scientific (Fair Lawn, NJ). Centricon molecular weight cutoff 
(MWCO) filters were obtained from Millipore (Burlington, MA). 
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2.2.2 ESI-MS Titration 
2.2.2.1 Sample preparation 
Each sample contained 2.5 μM β2m, 0 or 20 μM Cu(II)SO4, and 50 mM 
ammonium acetate. The concentrations of the small molecules were varied over an 
appropriate range to cover the Kd value. For the doxycycline-β2m samples, 20 μM of 
suramin was added and served as a reference ligand since β2m-doxycycline complexes 
were not readily measured in the mass spectrometer. The samples were incubated for up 
to 3 h at 37°C before analyzing the samples by ESI-MS. 
2.2.2.2 ESI-MS Titration Experiments 
Except for the cases of doxycycline-Cu(II)-β2m, all samples were measured by a 
Bruker AmaZon quadrupole ion trap mass spectrometer by direct infusion at a flow rate 
50 μL/h using a modified Bruker nanoflow sprayer. For the titration experiments, the 
MS-signal was optimized for the β2m charge state 7+ and 6+ and the associated non-
covalent complexes. The acquisition time for each sample was at least 3 min. To identify 
the appropriate small molecule concentrations for the covalent labeling studies, the 
dissociation constant (Kd) values for doxycycline, suramin and rifamycin SV bound to 
β2m were determined using previously described ESI-MS titration methods [31]. The 
values for suramin and rifamycin SV were determined directly. Kd of suramin was 
determined based on the equations below: 
𝐾𝑑 =  
1
𝐾𝑎
     (1)      𝐾𝑎 =
[𝑃𝐿]𝑒𝑞
[𝑃]𝑒𝑞∙[𝐿]𝑒𝑞
  (2) 
 
[𝑃𝐿]𝑒𝑞
[𝑃]𝑒𝑞
=
∑ 𝐼𝑛 (𝑃𝐿
𝑛+)
∑ 𝐼𝑛 (𝑃𝑛+)
= 𝑅    (3) 
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𝑅
𝑅+1
=
1+𝐾𝑎[𝑃]0+𝐾𝑎[𝐿]0−√(1+𝐾𝑎[𝑃]0−𝐾𝑎[𝐿]0)2+4𝐾𝑎[𝑃]0
2𝐾𝑎[𝑃]0
  (4) 
 
The following equations were used for rifamycin SV to account for the binding of 
two rifamycin SV molecules. The determined Ka values were then used to determine the 
Kd values, by assuming that Ka and Kd are inversely related. 
    (5) 
𝐾𝑎,𝑞 =
𝑅𝑞
𝑅𝑞−1([𝐿]0−
(𝑅1+2𝑅2+⋯+𝑞𝑅𝑞)[𝑃]0
1+𝑅1+𝑅2+⋯+𝑅𝑞
)
        (6) 
While for doxycycline a reference ligand method was applied [32] because the 
doxycycline-β2m complex is not preserved in the gas phase during the electrospray 
process. Ka of doxycycline is calculated by the following equations, based on previous 
work and the Kd value was determined by assuming that Ka and Kd are inversely related 
𝐾𝑎 =
𝑅
[𝐿]0−
𝑅
1+𝑅+𝑅𝑟𝑒𝑓
[𝑃]0
        (7) 
R =
𝑅𝑟𝑒𝑓
𝑅𝑒𝑥𝑝
− 1                    (8) 
Rexp is known from experiment result: 
[𝑃𝐿𝑟𝑒𝑓]𝑒𝑞
[𝑃]𝑒𝑞
=
∑ 𝐼𝑛 (𝑃𝐿𝑟𝑒𝑓
𝑛+)
∑ 𝐼𝑛 (𝑃𝑟𝑒𝑓
𝑛+)
= 𝑅𝑒𝑥𝑝            (9) 
Rref can be calculated with known Ka of reference ligand (suramin) from the 
following equation:  
𝑅𝑟𝑒𝑓 = 𝐾𝑎,𝑟𝑒𝑓 ([𝐿𝑟𝑒𝑓]0 −
[𝑃]0
𝑅𝑒𝑥𝑝
1+𝑅𝑒𝑥𝑝
)          (10) 
The Kd of doxycycline to Cu(II)-β2m were measured by the same Waters Synapt 
G2-Si quadrupole time-of-flight (QTOF) described in the main text. The electrospray 
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capillary voltage was set to 1.0 kV, while the source temperature was 30°C. The source 
offset was 10 and sampling cone was 150. Each sample contained 10 μM β2m, 20 μM 
Cu(II)SO4, 100 mM ammonium acetate, and 80 μM suramin. Concentration of 
doxycycline varies from 80 to 600 μM. 
2.2.3 Size Exclusion Chromatography 
For covalent labeling and size-exclusion chromatography (SEC) measurements, 
an 81 µL solution of 75 μM β2m was prepared in 18.5 mM MOPS (pH 7.4), 0.37 M urea 
and 0.11 M potassium acetate, with 150 μM Cu(II) (CuSO4). Stock solutions of 0.1 M 
doxycycline, 0.05 M rifamycin SV, and 0.025 M suramin were freshly prepared in 
distilled and deionized water. Samples containing β2m and doxycycline or suramin were 
incubated at 37 °C for 1 h before subjecting β2m to the measurements of interest. 
Rifamycin SV was incubated with β2m at 37 °C for 1 min before conducting the 
measurements of interest. 
Protein samples were separated by a SuperSW2000 SEC column (Tosoh 
Bioscience, LLC; Tokyo, Japan) with an HP Agilent (Wilmington, DE) 1100 HPLC 
system. The mobile phase contained 150 mM ammonium acetate (pH 6.8), and a flow 
rate 0.35 mL/min was used. Before injection, the SEC column was equilibrated by 
flowing the mobile phase for 30 min. 20 μL of a prepared sample or calibration standard 
was injected, and eluting proteins were detected by UV absorbance at 214 nm. A solution 
containing 5 μM bovine serum albumin (MW = 66000), 5 μM ovalbumin (MW = 45000), 
5 μM carbonic anhydrase (MW = 29040), and 5 μM β2m (MW= 11731) was used for 
molecular weight calibration. 
2.2.4 Circular Dichroism Spectroscopy 
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Circular dichroism was performed on a JASCO J-1500 (Easton, MD) to measure 
the impact of the small molecules on the secondary structure of β2m. Data were collected 
by scanning from 250 to 195 nm at 25 °C at a data pitch of 0.5 nm with a scan rate of 20 
nm/min. Each sample contains 50 μM β2m and 100 μM selected small molecule, with 25 
mM MOPS and 150 mM potassium acetate at pH 7.4 (the urea was omitted to generate 
higher quality CD spectra). Three scans were averaged per sample. Baseline subtraction 
and spectral smoothing was applied in JASCO Spectra Analysis. Data were then plotted 
in Origin. To estimate secondary structure content, JASCO’s CD Multivariate SSE was 
used. A protein data library was constructed using proteins with known structures and CD 
spectra provided by JASCO, and principal component analysis was used to calculate 
percent secondary structure values. 
2.2.5 Fluorescence Spectroscopy 
Each sample contains 2 μM β2m and 100 μM selected small molecule, with 25 
mM MOPS, 500 mM urea and 150 mM potassium acetate at pH 7.4. Prior to 
measurement, the samples were equilibrated at ambient room temperature (21 °C) for 10 
minutes. 
To measure the impact of the small molecules on the tertiary structure of β2m, a 
PTI Quantamaster 300 was used (Edison, NJ). Intrinsic fluorescence was measured via 
excitation separately at both 283 and 295 nm. Emission was monitored from 305 to 400 
nm. Data were collected at 1 nm intervals with an integration time of 1 second. Five 
scans were averaged per sample. Peaks were normalized from 0 to 1 to better compare 
λmax due to fluorescence quenching from inner filter effect. 
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For thermal stability experiments, data were collected on a JASCO 1500 CD 
Spectrophotometer equipped with a scanning emission monochromator and emission 
detector for fluorescence detection. Intrinsic tryptophan emission of β2m was measured 
every 1°C from 25 to 80°C via excitation at 295 nm while monitoring emission from 305-
400 nm. Prior to individual scans, samples were equilibrated at the new temperature for 1 
minute. λmax of each spectrum was determined by fitting the emission spectra to fourth 
order polynomial functions in Origin (Northampton, MA). For the control, the sample 
consisted of 3 μM β2m, 25 mM MOPS, 500 mM urea, and 150 mM potassium acetate at 
pH 7.4. A second control containing 6 μM CuSO4 was also measured. For the samples 
with suramin, doxycycline, or rifamycin SV added, the samples contained 3 μM β2m, 6 
μM CuSO4, 100 μM of the small molecule. Prior to all replicates, samples were incubated 
for 15 minutes at room temperature (21 °C). Samples were measured in triplicate and 
errors bars represent standard error of the mean.  
2.2.6 Covalent Labeling 
2.2.6.1 Sample Preparation 
Sample preparation is the same as described in 2.2.3. 
2.2.6.2 DEPC Labeling 
Stock solutions of DEPC were freshly prepared in acetonitrile. The reaction was 
initiated by adding a 0.8 µL aliquot of the DEPC stock solution so that there was a 
DEPC : protein molar excess of 4:1. In all cases, the final volume of acetonitrile was less 
than 1%. The reaction was allowed to proceed at 37 °C for 1 min, before being quenched 
by the addition of imidazole at a final concentration of 10 mM. These modification 
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conditions lead to 0.8 to 1.2 labels per protein on average, which is necessary to maintain 
the structure integrity of the protein during the modification reaction. These conditions 
have been established by numerous previous studies of DEPC labeling of β2m by our 
group [19, 21-23].   
2.2.6.3 BD Labeling  
Stock solutions of BD were freshly prepared in water. The reaction was initiated 
by adding a 3.3 µL aliquot of the BD stock solution so that there was a BD : protein 
molar excess of 1250 : 1. The reaction was allowed to proceed at 37 °C for 1 min, before 
being quenched by the addition of an arginine solution to a final concentration of about 
140 mM. These modification conditions lead to about 0.9 - 1.1 labels per protein on 
average, which ensures the structural integrity of the protein during the labeling reaction. 
2.2.6.4 EDC/GEE Labeling 
 Stock solutions of EDC and GEE were freshly made in 25 mM MOPS (pH 7.4) 
at a concentration of 50 mM and 2.0 M respectively. The reaction was initiated by adding 
an 18 µL aliquot of the EDC stock solution and an 18 µL aliquot of the GEE stock 
solution simultaneously; the EDC : GEE : protein molar excess was 150:6000:1. The 
reaction was allowed to proceed at room temperature for 30 min, before being quenched 
by the addition of formic acid to a final concentration of 0.1% (v/v). These modification 
conditions lead to about 0.4 labels per protein on average which ensures the structural 
integrity of the protein during the labeling reaction. 
2.2.7 Proteolytic Digestion  
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Before digestion of the proteins for LC/MS/MS analysis, the labeled protein 
samples were diluted with HPLC grade water to a volume of 400 µL and then 
concentrated using a 10,000 MWCO filter to a final volume of 20 µL. The samples were 
then brought to pH 8.0 by adding 70 µL of 100 mM triethylamine acetate. The disulfide 
bond was reduced at 37 °C for 10 min using TCEP at a protein : TCEP molar ratio of 
1:80, and the resulting reduced cysteines were alkylated in the dark for 30 min using 
iodoacetamide at a protein : iodoacetamide molar ratio of 1:80. Next, the samples were 
incubated with 10% (v/v) acetonitrile at 50 °C for 45 min to denature the protein. The 
protein sample was then applied to the selected enzyme at an enzyme : substrate ratio of 
1:10. Digestion of DEPC and BD labeled proteins were performed with immobilized 
chymotrypsin. EDC/GEE labeled proteins were divided into tubes with equal volumes 
before either immobilized chymotrypsin or immobilized trypsin was added. After 2 h of 
digestion at 37 °C, the enzyme was separated from the mixture by centrifugation, and the 
precipitate was discarded. In the case of the EDC/GEE labeled proteins, the peptide 
mixture generated by the two enzymes was then mixed at equal volume and analyzed at 
the same time.  
2.2.8 Liquid Chromatography-Mass Spectrometry (LC-MS) 
All protein digests were measured immediately after proteolytic digestion by LC-
MS. Mass analysis was carried out on a Bruker AmaZon (Billerica, MA) quadrupole ion 
trap mass spectrometer equipped with an electrospray ionization source. Typically, the 
electrospray needle voltage was kept at ∼4 kV, and the capillary temperature was set at 
220 °C. Either collision-induced dissociation (CID) or electron transfer dissociation 
(ETD) was applied to identify the position of the labels. 
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HPLC separation was conducted by a Thermo Scientific (Waltham, MA) Ultimate 
3000 HPLC with a Thermo Acclaim PepMap RSLC C18 column (300 µm x 15 cm, 2 µm 
particle size). Peptide mixtures from the proteolytic digests were eluted using a gradient 
of acetonitrile containing 20% water and 0.1% formic acid that increased from 5% to 
45% for 45 min at a flow rate of 4 µl/min. 
2.2.9 Determination of Modification Percentages  
The modification percentage of each amino acid was determined in the same 
manner as described previously [21-25] Briefly, the ion abundance of each peptide of 
interest (i.e. labeled or unlabeled) was determined from extracted ion chromatograms 
(e.g. Figure 2.1). For peptides that contain more than one modified amino acid, it was 
possible to separate the isomeric peptides (e.g. Figure 2.1), thereby allowing 
measurements of individual amino acid modification levels. The % modification was 
calculated based on eq 11. The modified ion intensities (Iunmodified) used in equation 1 are 
the sum of the total ion intensities of all the peptides that contain the modified amino acid 
of interest. Averaged ion intensity across the selected peak areas of individual peaks were 
used to determine ion intensity. The percent modification is a relative rather than an 
absolute value because the modified and unmodified peptides have different ionization 
efficiencies. 
% modification=  Imodified/(Imodified+Iunmodified )  x 100                  (11) 
Reported percent modifications are averages from three separate experiments. A 
two-sample unpaired student’s t-test at a 95% confidence interval was used to determine 
if changes in modification levels with and without small molecules were significantly 
different.  
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Figure 2.1 Extracted ion chromatogram for relative labeling ratio calculation. 
Extracted ion chromatogram of m/z 329.2 (green), which is the +3 ion of the unmodified 
peptide 88SQPKIVKW95; extracted ion chromatogram of m/z 529.3 (pink), which is the 
+3 ion of the single DEPC unmodified peptide 88SQPKIVKW95. 
 
2.2.10 Ion Mobility Mass Spectrometry 
A Waters Synapt G2-Si quadrupole time-of-flight (QTOF) that was equipped with 
a nanospray source was used to collect native mass spectral data. Both the mass spectral 
and ion mobility data were obtained at the University of Massachusetts Mass 
Spectrometry Center. Electrospray capillaries were prepared in-house by sputter coating 
gold using a Cressington 108 onto pulled borosilicate thin-wall capillaries (Harvard 
Apparatus, cat#30-0035, Holliston, MA) in a manner similar to established protocols 
[33]. The electrospray capillary voltage was set to 1.0 kV, while the source temperature 
was 30°C. The m/z scale was calibrated from 500-8,000 using perfluoroheptanoic acid 
(PFHA). The source offset and sampling cone were set to 20 V. Samples were incubated 
for 6 days at 37°C in solution conditions similar to the labelling experiments. 
Immediately prior to analysis, the samples were removed from the incubation chamber 
and desalted into 100 mM ammonium acetate using a HiTrap column (GE Healthcare, 
Chicago, Illinois). The desalting process yielded a final sample concentration of 
approximately 10 μM. Data for each sample was acquired for 10 minutes and averaged 
over that duration. Collisional cross section (CCS) values were estimated from a linear 
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calibration curve of native-like protein ions using a method described elsewhere [34] The 
R2 for this curve was 0.98. Data analysis was carried out using Waters MassLynx and 
Driftscope. The extracted arrival time distributions (ATDs) were plotted using Origin. 
2.2.11 Protein-Ligand Docking 
 Protein-ligand docking was carried out using Glide (Version 2016-1, 
Schrodinger, LLC, New York). The β2m monomer NMR structure (PDB ID 1JNJ, first 
one of the 20 structures) was used as a starting point and was processed and optimized by 
Protein Preparation Wizard, setting PROPKA at pH=7.0. The 3D SDF structures of 
doxycycline and rifamycin SV, 2D structure of suramin (3D structure not available) were 
downloaded from PubChem (pubchem.ncbi.nlm.nih.gov). All the small molecule 
structures were then prepared with LigPrep with forcefield OPLS3 applied. Chiralities of 
3D structure were maintained and possible states at the target pH 7.4 ± 0.5 were 
generated. A grid was generated with centroid of specified coordinates (centered on β2m) 
that enabled the entire β2m monomer structure to be covered by adjusting the size of 
ligand diameter midpoint box, and no other constraint was applied. The docking was 
performed using Ligand Docking with Extra Precision (XP) mode. The number of poses 
to be reported was not limited, but post-docking minimization was applied with 20 poses 
per ligand included with strain correction terms. After the above steps, all the reported 
results were ranked by Docking Scores, and poses with Docking Score above zero were 
excluded. 
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2.3 Results and Discussion 
2.3.1 Kd Values for β2m with Selected Molecules  
We first determined the Kd values for each of the three molecules when binding to 
monomeric β2m. Measuring the Kd values was important for confirming that the 
molecules bind to β2m at the relevant concentrations used in the subsequent covalent 
labeling experiments. Kd values were measured via ESI-MS titration using an approach 
that is similar to previous work [31, 32]. Figure 2.2 shows example mass spectra, Figure 
2.3 shows an example of the titration data obtained for suramin. The determined Kd 
values for doxycycline and suramin are 200 ± 20 μM and 40 ± 2 μM, respectively, 
whereas for rifamycin SV, two Kd values are measured: Kd1  = 250 ± 25 μM and Kd2  = 80 
± 20 μM. These results confirm that the molecules bind to the β2m monomer, even 
though their affinities for β2m are relatively weak. 
 
Figure 2.2 Example ESI-MS spectrum of suramin-Cu(II)-β2m. 
Sample included β2m (2.5 μM) with suramin (12.5 μM) and 20 μM Cu(II), in ammonium 
acetate buffer (50 mM). 
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Figure 2.3 ESI-MS titration curve indicating the binding affinity of suramin to 
Cu(II)-β2m. 
2.3.2 Size Exclusion Chromatography.  
The measured Kd values allow us to identify concentrations of each small 
molecule needed to maximize the β2m-molecule complex concentration so that the 
covalent labeling experiments could be as sensitive as possible. Because we wanted to 
measure binding sites under conditions in which β2m is known to form amyloid and 
because we previously found that the inhibitors (i.e. rifamycin SV and doxycycline) can 
influence the formation of off-pathway pre-amyloid oligomers [10], we needed to 
optimize the small molecule concentrations used in the covalent labeling experiments to 
ensure that Cu(II)-β2m was still monomeric in the presence of the molecules of interest. 
Thus, we identified the highest concentration of each small molecule that could be used 
without observing any protein aggregation during the 1 min covalent labeling reaction. 
SEC was used to measure the extent of β2m oligomer formation at different 
concentrations of doxycycline, rifamycin SV, and suramin. From the SEC results (see 
example chromatograms in Figures 2.4 and 2.5), we found that up to 1.8 mM of 
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doxycycline and 0.22 mM of suramin could be added without significant β2m 
aggregation being observed within 1 h. In both cases, these concentrations correspond to 
over 85% of the protein being bound to the given molecule. In contrast, only 0.25 mM of 
rifamycin SV could be added without generating a significant amount of β2m oligomers 
in 1 min. Under these conditions, about 33% of the Cu(II)-β2m complexes are not bound 
to rifamycin SV. 
 
Figure 2.4 Example SEC chromatograph for β2m incubated with Rifamycin SV. 
High concentration of rifamycin SV (1.78 mM) will generate β2m oligomers (>M6), 
while 0.25 mM rifamycin SV will not. 
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Figure 2.5 Example SEC chromatograph for β2m incubated with doxycycline and 
suramin. 
High concentration of doxycycline (1.8 mM) or suramin (0.22 mM) will only generate 
minor amount of oligomer under selected experimental labeling conditions. 
2.3.3 Rifamycin SV Binding 
The β2m-Cu(II) complex was covalently labeled in the presence and absence of 
rifamycin SV as a way to identify the binding site of this molecule. DEPC was first used 
because it can modify a wide range of amino acids, including His, Lys, Ser, Thr, Tyr, and 
the N-terminus. Results from the DEPC labeling experiments are shown Figure 2.6.1. 
Upon binding rifamycin SV, Lys6, Lys91 and Lys94 are found to undergo significant 
decreases in labeling, while the N-terminus undergoes a significant increase in labeling. It 
should be noted that the extents of the labeling changes are small in many cases, but the 
reproducibility of the experiments is usually sufficient to confidently distinguish even 
small changes. The reason for the small changes in labeling extent is likely attributed to 
the fact that about 33% of Cu(II)-β2m complex is not bound to rifamycin SV for the 
conditions under which we performed the covalent labeling experiments.  
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Figure 2.6 CL-MS results of rifamycin SV with Cu(II)-β2m 
(1) Changes in covalent labeling modification percentages with rifamycin SV bound to 
the Cu(II)-protein complex. Error bars represent a single standard deviation from three 
replicate measurement. Asterisks above the bars represent the residues that undergo a 
significant change in modification level at a 95% confidence interval as determined by a 
two-sample unpaired Student’s t-test. The arrows at the top of the graph indicate the 
locations and directions of the seven β strands in β2m. (2) Ribbon structure of β2m, 
showing the seven β strands labeled A through G. (3) β2m surface structure illustrating 
the sites of significant changes in covalent labeling induced by rifamycin SV. Sites that 
increase in labeling are colored red, while sites that decrease in labeling are colored blue. 
(4) Protein-ligand docking result. 
 
To assess the potential rifamycin SV binding site, the covalent labeling results 
were mapped on the NMR structure (PDB ID 1JNJ) of the Cu(II)-free protein. This 
structure was selected as the model because other work had demonstrated that Cu(II) 
binding does not dramatically change the native β2m structure [19, 35]. (Note: no Cu(II)-
β2m monomer structures are available.) Upon considering the protein model structure, it 
  41 
is clear that Lys6, Lys91 and Lys 94 are in relatively close proximity to each other, with 
about 17 Å between Lys6 and Lys91 and 12 Å between Lys91 and Lys94. Given the size 
of rifamycin SV, which is approximately 14 x 7 Å, the flexibility of the lysine side 
chains, and the fact that Cu(II)-binding causes only minor structural changes to β2m [19, 
35], the DEPC labeling results narrow down the binding site to an area near the A and G 
β strands. The reason for the increased labeling at the N-terminus is not clear at this stage, 
but it could potentially reflect an allosteric change caused by rifamycin SV binding.  
To obtain additional confirmation of the binding site and further narrow down the 
β2m residues that interact with rifamycin SV, we employed two other types of labels. The 
arginine-selective reagent 2,3-butanedione (BD) was selected because Arg3 and Arg12 
flank the residues that are part of the A β strand, Arg97 is near the G β strand, and Arg45 
is on the opposite side of the protein (see Figure 2.7). We predicted that changes in the 
extent of labeling of the nearby Arg residues would further help narrow potential 
rifamycin SV binding sites. From the BD labeling results (Figure 2.6.1), only Arg97 is 
found to undergo a significant change in labeling, as its labeling percentage decreases 
from 6.4 ± 0.3 to 5.4 ± 0.2 in the presence of rifamycin SV. Insignificant labeling 
changes to Arg3, Arg12, and Arg45 along with a decrease in Arg97 labeling suggest that 
rifamycin SV binds predominantly along the G β strand. 
We also used the reagent pair EDC/GEE to monitor changes in the solvent 
accessibility of Asp and Glu residues. Seven Asp and Glu residues are modified by 
EDC/GEE, including Glu16, Asp34, Glu36, Asp38, Glu50, Asp53, and Asp59, but none 
of these residues undergo a significant change in labeling, which is not surprising 
considering that all but one of these residues are located on the opposite face of the 
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protein (see Figure 2.8) from the residues identified by DEPC and BD labeling. The fact 
that there is no change in labeling on Glu16, which is located on the loop that is between 
the A and B β strands, further confirms that rifamycin SV is not binding in this region of 
the protein but is binding closer to the G β strand. 
 
Figure 2.7 BD labeling assists with rifamycin SV binding site identification.  
Lys6, Lys 91 and Lys94 form a cluster that rifamycin SV could possibly near. Arg3, 
Arg12 and Arg97 are near this cluster, and their labeling could further narrow down the 
binding site. 
 
Figure 2.8 EDC/GEE labeling assists with rifamycin SV binding site identification. 
The cluster of significantly decreased sites include Lys6, Lys91, Lys 94 and Arg97. 
Asp16 is the only Asp/Glu that is close to this cluster. 
 
Protein-ligand docking was also performed using the program Glide from the 
Schrödinger software suite to predict rifamycin SV’s binding site on β2m. The Cu(II)-
free β2m monomer (PDB ID 1JNJ) was used as the protein model, even though β2m’s 
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CD spectroscopy (Figure 2.9.1), ion mobility (Figure 2.9.3), its fluorescence λmax (Figure 
2.9.5 and 2.9.6), and thermal stability (Figure 2.10) data reveal rifamycin SV binding 
slightly perturbs the native β2m structure. It should be noted that while it is known that 
Cu(II) binding does not have a dramatic effect on β2m structure [19, 35], it does have a 
measurable effect on β2m thermal stability (Figure 2.10). In comparison, rifamycin 
binding to the Cu(II)-bound protein stabilizes the structure to be more similar to the 
native. Thus, in the absence of any other β2m structural model, we feel that the chosen 
model structure is a reasonable starting point for docking experiments. Upon using this 
structural model for docking, we find that the predicted binding site is the pocket between 
Lys75 and Arg97 (Figure 2.6.4). In light of our covalent labeling, we conclude that 
rifamycin SV likely binds near Lys94 and Arg97 and perhaps Lys91, which is along the 
G β strand of the protein. A perfect match between the docking and labeling results is not 
expected given the fact that rifamycin SV mildly perturbs the native structure of β2m 
(Figure 2.10), but the similarity is encouraging. The decreased labeling of Lys6 may be 
due to its proximity to the other residues, subtle structural changes that the protein 
undergoes upon binding to rifamycin SV, or could perhaps be due to burial in the small 
fraction of protein molecules that have a second rifamycin SV bound to them.  
More importantly, the binding site that is identified by covalent labeling is 
consistent with what is known about pre-amyloid oligomeric β2m structures [21, 22] and 
our recent work on β2m amyloid inhibition by rifamycin SV [10]. Our group recently 
showed that rifamycin SV inhibits β2m amyloid formation by preventing the β2m dimer 
from forming an amyloid-competent tetramer. We had previously found that the β2m 
tetramer is formed by two dimers interacting between the G β strands and the D β strands 
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[22]. Considering the binding site identified in the current work, rifamycin SV’s proposed 
mode of action for preventing β2m amyloid formation is to bind near the G β strands (i.e. 
Figure 2.6) and prevent two dimers from forming an amyloid-competent tetramer. 
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Figure 2.9 Structure similarity of Cu(II)-β2m with doxycycline, rifamycin SV, or 
suramin to Cu(II)-β2m monomer. 
 (1) Comparison of changes in secondary structure of β2m in the presence of small 
molecules. (2-4) comparing arrival time distribution and collisional cross section reveals 
expanded states in the gas phase for monomeric β2m when bound to small molecules, 
doxycycline (2), rifamycin (3), and suramin (4). (5-6) comparison of changes in tertiary 
structure via intrinsic fluorescence of β2m in the presence of small molecules. Emission 
spectra following excitation at 295 nm (5) and 283 nm (6). 
(1)  
(2) 
 
(3) 
 
(4) 
 
(5) (6) 
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Figure 2.10 Effect of small molecules on thermal stability of β2m. 
Tm of β2m, Cu(II)-β2m, and Cu(II)-β2m with rifamycin SV , doxycycline, or suramin 
were measured. The thermal stability of β2m was assessed using intrinsic tryptophan 
fluorescence at 295 nm in triplicate. Calculated midpoint Tm values are summarized in 
the inset table. Error bars represent the standard error of the mean. 
 
2.3.4 Doxycycline Binding 
The binding site of doxycycline was determined in a similar manner to rifamycin 
SV. DEPC labeling was first applied and numerous residues undergo significant changes 
in labeling (Figure 2.11). More sites undergo significant changes than with rifamycin SV, 
and this increased number of residues is probably because more than 90% of Cu-protein 
complex is bound to doxycycline. Again, the Cu(II)-free β2m NMR structure (PDB ID 
1JNJ) is used to map the labeling changes for reference. The sites that undergo decreased 
labeling can be clustered into two primary groups: 1) Lys6, Lys91, and Lys94, and 2) 
Lys41, Lys48 and His51/Ser52. This clustering of residues is based on the distribution of 
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these sites on the protein surface and the size of one doxycycline molecule (about 13 x 7 
Å). Lys75 and Ser57/Lys58 are not included in either group because they are somewhat 
distant from each cluster of residues. It is difficult to exclude either group based on the 
extent of the labeling decrease because allosteric changes or changes in the local 
microenvironment can alter the reactivity of residues for reasons other than decreased 
solvent accessibility. These possible changes are particularly true for Lys residues, as 
disruption of salt bridges or changes in pKa, due to microenvironment changes, can 
influence their reactivity with DEPC [36]. 
Interestingly, the N-terminus, His13, Ser28, His31 and Ser33 all undergo 
significant increases in labeling. Among these five residues, the N-terminus, Ser28, 
His31 and Ser33 are close to or part of the known Cu(II) binding site [19, 35]. Increased 
labeling at these residues suggests that Cu(II) binding is affected by doxycycline binding. 
Indeed, as we reported in recent work, β2m’s affinity for Cu(II) decreases by 
approximately 25-fold in the presence of doxycycline [10]. The increased labeling extent 
of His13 is more difficult to explain but may be due to an allosteric change. 
EDC/GEE labeling was again applied to narrow down potential binding sites. As 
shown in Figure 2.12, Glu50 and Asp53 are near His51, offering a potential means of 
distinguishing the second group of residues identified by DEPC labeling (i.e. Lys41, 
Lys48 and His51/Ser52) from the first group (i.e. Lys6, Lys91, and Lys94). We find that 
only Glu50, of all the Asp and Glu residues, undergoes a significant decrease in labeling, 
which is consistent with doxycycline binding near the cluster defined by Lys41, Lys48, 
and His51/Ser52 but not the cluster defined by Lys6, Lys91, and Lys94. Moreover, 
Asp34, Glu36, and Asp38 are on the same C β strand as Lys41, but these residues do not 
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undergo a decrease in labeling, indicating that doxycycline is not binding to residues on 
the C β strand. The fact that both Glu50 and Asp53 are on the same D β strand as Lys48 
and His51/Ser52, but only Glu50, not Asp53, undergoes a significant labeling decrease 
suggests that doxycycline only binds to the beginning of D β strand. 
 
Figure 2.11 CL-MS results of doxycycline with Cu(II)-β2m 
(1) Changes in covalent labeling modification percentages with doxycycline bound to the 
Cu(II)-protein complex. Error bars represent a single standard deviation from three 
replicate measurement. Asterisks above the bars represent the residues that undergo a 
significant change in modification level at a 95% confidence interval as determined by a 
two-sample unpaired Student’s t-test. The arrows at the top of the graph indicate the 
locations and directions of the seven β strands in β2m. (2) β2m surface structure 
illustrating the sites of significant covalent labeling changes induced by doxycycline. 
Sites that increase in labeling are colored red, while sites that decrease in labeling are 
colored blue. (3) Protein-ligand docking result. 
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Because no Asp or Glu residues are near the first cluster of residues identified by 
DEPC labeling, we further investigated the binding site by BD labeling. Arg3, Arg45, 
and Arg97 surround cluster 1 (Figure 2.13). Arg3 and Arg97 undergo an increase in 
labeling, suggesting that doxycycline is not binding near Lys6, Lys91, or Lys94. The 
changes in the labeling of these Lys residues may be caused by DEPC reactivity 
decreases caused by changes in the nearby microenvironment. Interestingly, the labeling 
extent of Arg45, which is near Lys41, does not change significantly. Alongside the lack 
of labeling changes associated with Asp34, Glu36, and Asp38, no apparent change in the 
labeling extent at Arg45 further suggests that doxycycline does not bind to the C β strand. 
Considering the labeling results as a whole, we conclude that doxycycline binds near 
Lys48, Glu50 and His51/Ser52. These residues all undergo significant decreases in 
labeling ratio and all are located on the beginning of D β strand. 
We also used protein-ligand docking with Glide to predict the doxycycline 
binding site on β2m. The Cu(II)-free β2m monomer (PDB ID 1JNJ) was again used as 
the protein model because the CD spectroscopy (Figure 2.9.1), ion mobility (Figure 
2.9.2), its fluorescence λmax (Figure 2.9.5 and 2.9.6), and thermal stability (Figure 2.10) 
data indicate that doxycycline binding only slightly perturbs the protein’s structure. 
Indeed, the doxycycline appears to perturb the structure even less than rifamycin SV, 
suggesting that the chosen model is even more appropriate for docking. Using this 
structural model, docking predicts a binding site that is in the pocket between the C and 
D β strands (Figure 2.11.3). This docking position is very consistent with the labeling 
data that shows several residues on the D β strand, including Lys48, Glu50, and 
His51/Ser52, undergoing significant changes in labeling (Figure 2.14). Given the fact that 
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several residues on C β strand have no significant changes in the labeling degree and 
decreases in labeling are observed along the D β strand, it is reasonable to conclude that 
doxycycline binds near the D β strand. 
Binding at the D β strand is consistent with our group’s recent work that shows 
doxycycline can redirect β2m amyloid formation by perturbing the β2m dimer structure 
such that it cannot form an amyloid-competent tetramer [10]. As indicated above and as 
previously shown, the β2m tetramer is formed by two dimers interacting between the G β 
strands and D β strands [22]. Binding of doxycycline to the D β strand, as indicated by 
our labeling results, reveals how the amyloid formation pathway can be redirected to 
form non-amyloid aggregates. It should be noted that Giorgetti et al. studied 
doxycycline/β2m binding by NMR and identified a different binding site that involves β 
strands A and B [8]. These measurements, however, were done under non-amyloid 
forming conditions in which the protein was present in pure water at a pH between 5.5 
and 6. The difference in the binding site that we identify as compared to this previous 
study likely reflects the fact that the protein likely has a significantly different structure 
under amyloid-forming conditions at pH 7.4, which are the conditions we have used in 
our studies here. 
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Figure 2.12 EDC/GEE labeling assists with doxycycline binding site identification.  
Ribbon structure of β2m monomer showing the distribution of glutamic and aspartic 
acids that can be labeled by EDC-GEE. Cluster 1 includes Lys6, Lys91 and Lys94, and 
Glu16 is the closest to this cluster. Cluster 2 includes Lys41, Lys48 and His51/Ser52, and 
Asp50 and Glu53 are near this cluster. 
 
Figure 2.13 BD labeling assists with doxycycline binding site identification. 
Ribbon structure of β2m monomer showing the distribution of arginine residues that can 
be labeled by BD. Cluster 1 includes Lys6, Lys91 and Lys94, and Arg3, Arg12 and 
Arg97 are close to this cluster. Cluster 2 includes Lys41, Lys48, Asp50 and His50/Ser52, 
and Arg45 is next to this cluster.   
 
 
Figure 2.14 Labeling experiment result and docking result presenting on the protein 
surface structure: doxycycline. 
A residue significant change in labeling upon doxycycline binding is marked in blue 
(decrease) or red (increase). Docking and CL experiment results both indicate 
doxycycline binding site is close to D β strand. 
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2.3.5 Suramin Binding 
Suramin binds with greater affinity to β2m than doxycycline and rifamycin SV, 
but as described previously it does not inhibit amyloid formation [10]. Thus, we 
hypothesized that the identity of the suramin binding site would be different from the 
doxycycline and rifamycin SV binding sites such that it would not interfere with 
oligomer formation. DEPC labeling results in four sites that decrease in labeling (Figure 
2.15.1), and these sites are clustered into two groups based on proximity and suramin’s 
size: 1) Lys41 and Lys48 and 2) the N-terminus and Ser57/Lys58. Suramin is a larger 
molecule than doxycycline and rifamycin SV, and it is less conformationally constrained 
than the other two, which suggests that it could potentially cover a larger area of β2m’s 
surface.  
With relatively little distinguishing information obtained from DEPC labeling 
alone, we also used EDC/GEE labeling to narrow further the binding site. Several Asp 
and Glu residues along the C and D β strands can be probed (Figure 2.16), and strikingly 
Asp34, Glu36, and Glu50 all undergo significant decreases in labeling (Figure 2.15.1). 
These three residues are positioned near Lys41 and Lys48, suggesting that suramin binds 
near the C and/or D β strand, rather than near the N-terminus. Curiously, Asp38 and 
Asp53 undergo increased labeling despite being positioned on the C and D β strands. 
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Figure 2.15 CL-MS results of suramin with Cu(II)-β2m. 
(1) Changes in covalent labeling modification percentages with suramin bound to the 
Cu(II)-protein complex. Error bars represent a single standard deviation from three 
replicate measurement. Asterisks above the bars represent the residues that undergo a 
significant change in modification level at a 95% confidence interval as determined by a 
two-sample unpaired Student’s t-test. The arrows at the top of the graph indicate the 
locations and directions of the seven β strands in β2m. (2) β2m surface structure 
illustrating the sites of significant covalent labeling changes induced by suramin. Sites 
that increase in labeling are colored red, while sites that decrease in labeling are colored 
blue. (3) Proposed suramin binding site based on covalent labeling data. 
 
BD labeling was used further to identify the suramin binding site. Consistent with 
the EDC/GEE labeling decreases found for residues on the C β strand, Arg45, which is 
also on the C β strand (Figure 2.17), undergoes a significant labeling decrease (Figure 
2.15.1). The three other Arg residues in the protein, including Arg3, which is near the N-
terminus, do not undergo significant changes in labeling. Considering the labeling data as 
a whole, the suramin binding site appears to be located along the C β strand and the C-D 
loop, based on the decreased labeling of Asp34, Glu36, Lys41, Arg45, and Lys48 (Figure 
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2.15.2). The distance from Asp34 to Lys41 is approximately 23 Å, which can be easily 
spanned given the molecular dimensions of suramin. Moreover, suramin has negatively 
charged sulfonate groups that could likely bind to Lys41, Arg45, and Lys48. These 
sulfonate groups might also explain why Asp38, and perhaps Asp53, undergo increased 
labeling as they are electrostatically repelled by the sulfonate groups and made more 
solvent accessible. As expected from the outset, this binding site along the C β strand is 
in contrast to the doxycycline and rifamycin SV binding sites. 
Once again, protein-ligand docking was considered for predicting the suramin 
binding site on β2m. Because the CD spectroscopy (Figure 2.9.1), ion mobility (Figure 
2.9.3), its fluorescence λmax (Figure 2.9.5 and 2.9.6), and thermal stability (Figure 2.10) 
measurements suggest β2m’s structure is significantly perturbed upon suramin binding, 
we did not expect good agreement between the docking and covalent labeling results. 
Indeed, all 7 poses with docking scores below zero place suramin near the N-terminus or 
near the A or D β strands (Figure 2.18 and Table 2.1). These poses do not agree well with 
the labeling data. In fact, these docking results position suramin near the known β2m 
dimer interface [21, 22], which is inconsistent with suramin’s inability to inhibit β2m 
amyloid formation or the progression of the oligomers that precede amyloid formation 
[10]. Thus, we conclude that the docking results are inaccurate, highlighting the value of 
experimental labeling data. This inconsistency between theory and experiment likely 
arises because the β2m model used for docking is probably not a good one. 
Based on the labeling results, we conclude that suramin binds along the C β strand 
and near the C-D loop (Figure 2.15.3), which is consistent with the observation that 
suramin is not capable of inhibiting β2m amyloid formation [10]. From our previous 
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studies of β2m oligomer structures [21, 22], the C β strand has not been implicated as 
part of the interface in either dimer or tetramer. Binding of suramin to this region of the 
protein then likely explains why it does not substantially influence β2m amyloid 
formation. 
 
Figure 2.16 EDC/GEE labeling assists with suramin binding site identification. 
Ribbon structure of β2m monomer showing the distribution of glutamic and aspartic 
acids that are labeled by EDC-GEE. Cluster 1 includes Lys41 and Lys48, and Asp34, 
Glu36, Asp38 and Glu50 are the close to this cluster. Cluster 2 includes N-terminus and 
Lys58/Ser57, and Asp59 is near this cluster. 
 
Figure 2.17 BD labeling assists with suramin binding site identification. 
Ribbon structure of β2m monomer showing the distribution of arginine residues that are 
labeled by BD. 
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Figure 2.18 Top Glide docking predicted suramin binding pose compared to 
experiment result. 
A residue significant change in labeling upon suramin binding is marked in blue 
(decrease) or red (increase). Results show inconsistent between docking result and CL 
proposed suramin binding site.   
 
Table 2.1 Suramin docking score. 
Pose 
Rank 
Docking 
Score 
1 -3.077 
2 -2.685 
3 -2.569 
4 -2.189 
5 -1.147 
6 -1.011 
7 -0.812 
*All docking results from Glide docking, ranked by docking score from lowest to 
highest. The most negative docking score indicates the best docking results according to 
the Glide algorithm. 
 
2.4 Conclusion 
Our results indicate that covalent labeling together with MS is a useful tool for 
studying protein-ligand binding sites. Changes in labeling extents in clusters of adjacent 
amino acid residues, with and without ligand molecules present, allow ligand binding site 
information to be obtained. Confidence in the binding site determination is notably 
improved when multiple covalent labeling reagents are used together. Using DEPC, BD, 
  57 
and the EDC/GEE pair as labeling reagents, we identify the binding sites of two small-
molecule inhibitors of β2m amyloid formation. The identified binding sites are consistent 
with the known effects of these molecules and with molecular docking results, thereby 
providing validation of the covalent labeling method. Rifamycin SV is found to bind to 
β2m on the G β strand, while doxycycline binds on the D β strand of β2m. These binding 
sites are near the known interfaces of the pre-amyloid tetramer of β2m [22] and are 
consistent with previous measurements that indicate that these molecules inhibit amyloid 
formation by preventing the amyloid-competent tetramer from forming [10]. Moreover, 
the binding site of suramin, which does not inhibit β2m amyloid formation, occurs near 
the C β strand and C-D loop of the protein, a region not involved in any known oligomer 
interface, further validating the accuracy of the covalent labeling method. The fact that 
three molecules bind to different sites on β2m may seem surprising, given the small size 
of the protein, but its β-sandwich structure presents distinct surface regions and inter-
sheet binding pockets that evidently can be exploited by the three chemically different 
molecules.  The covalent labeling/MS method described here appears to be suitable for 
providing protein-ligand binding information for systems that are difficult to study by 
other methods. In addition, the method might be used to facilitate drug design efforts by 
improving the targeted virtual screening of compound libraries by narrowing the protein 
sites most likely to influence a protein’s reactivity. 
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CHAPTER 3 
 
PROTEIN-LIGAND AFFINITY DETERMINATIONS USING COVALENT 
LABELING-MASS SPECTROMETRY 
 
Marcinko, T. M. contributed to this work by conducting the fluorescence spectroscopy 
and size exclusion chromatography measurements for characterizing the EGCG and 
Cu(II)-β2m complex described in this chapter. 
 
3.1 Introduction 
Understanding the details of protein-ligand interactions has implications for drug 
discovery, design, and development [1, 2]. As a part of characterizing protein-ligand 
complexes of interest, binding affinity determination is a critical aspect. To acquire the 
binding affinity of the ligand to the protein, mass spectrometry (MS) based methods have 
been explored as one of the options because the advantages of the technique. Inherent 
advantages of MS such as specificity, small sample consumption, and simplicity (e.g. no 
immobilization needed) are appealing aspects of this approach [3]. Native electrospray 
ionization mass spectrometry (ESI-MS) allows noncovalent protein-ligand complexes to 
be transferred intact from solution to the gas phase [4-6], which makes ESI-MS-based 
titration experiments possible [7, 8]. However, although the ESI process can be gentle 
enough to preserve the protein-ligand complexes as they are ionized, there are still 
possibilities that the ion mixture measured by MS does not reflect the original 
components in solution. For example, the protein and protein-ligand complex could have 
different ionization and detection efficiencies. Protein-ligand complexes might also 
undergo in-source dissociation either due to the ligand binding weakly to the protein, 
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improper instrument settings, or non-specific ligand binding to the protein or protein-
ligand complex that could cause false positives [3].  
As ESI-MS signals do not always reflect the analyte concentration in solution, 
other MS-based methods that encode protein-ligand binding information into mass shifts 
have been developed. For example, hydrogen deuterium exchange (HDX)-based methods 
have been used to measure the dissociation constants (Kd) for protein-ligand complexes. 
One of the first examples was the method known as SUPREX (stability of unpurified 
proteins from rates of H/D exchange) [9], which utilizes denaturants to monitor the 
relative stabilities of a protein and its ligand complex to obtain a Kd [10]. Another HDX-
MS method to determine Kd values is PLIMSTEX [11, 12], which relies on labeling in 
the context of ligand titration. PLIMSTEX also offers information about protein-ligand 
stoichiometries and dynamics at the same time. When residue or peptide-level 
information is obtained during these experiments, the binding site can be often acquired. 
For HDX-based methods, back exchange is a concern, and the need to measure 
multiple exchange time points can make the measurements time consuming. Covalent 
labeling (CL)-based methods can avoid these challenges as the covalent bond that is 
formed limits label loss, and multiple time-point measurements are not needed [13-16]. 
Recently, a method based on fast photochemical oxidation of proteins (FPOP) called 
LITPOMS (ligand titration, fast photochemical oxidation of proteins and mass 
spectrometry) [17, 18] was reported. LITPOMS uses hydroxyl radicals to modify the 
protein of interest, and then relies on decreased protein oxidative modification that occurs 
at the ligand binding site as the ligand concentration is increased. The method yields 
information about ligand binding affinities, binding sites, and even ligand-induced 
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structural changes when combined with bottom-up sequencing. As compared to HDX-
based methods, CL methods like LITPOMS require little sample dilution, making it 
easier to study weakly binding protein-ligand complexes. Given the potential advantages 
of CL for determining Kd values, we were interested in assessing if other CL methods and 
reagents could provide reliable protein-ligand binding constants. In particular, CL 
methods that do not require sophisticated equipment (e.g. laser or flow cell) and are 
simpler to use were sought. The work described here focuses on CL methods that do not 
use radical-based reagents. It is known that CL-MS, including non-radical CL methods, 
are able to identify the ligand binding sites of proteins [13, 19-22] by identifying residues 
that undergo decreases in labeling due to ligand-induced decreases in solvent 
accessibility of the residues involved in binding. If such CL is applied in a ligand titration 
context, Kd values should be accessible.  
A key concern with non-radical based labeling reagents is their relatively slow 
reaction kinetics, which are on the order of milliseconds to seconds [14, 23] as compared 
to radical-based CL reagents that react on the sub-millisecond timescale [24, 25]. The 
slower reaction timescale might mean that the ligand dissociation and re-association 
processes that are a normal part of the equilibrium could occur on comparable timescales, 
yielding incorrect binding information because the labeling distorts the original binding 
equilibrium. Such a concern is presumably not present with radical-based methods such 
as FPOP because labeling happens on a faster timescale than ligand dissociation/re-
association. We predict that relatively accurate binding constants can be obtained using 
slower labeling reagents as long at the extent of protein labeling at the binding site is 
minimized enough to prevent significant label-induced changes to the equilibrium. In this 
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work, we use several model protein-ligand complexes to demonstrate this idea. We find 
that reasonably accurate Kd determinations can be made when the extent of protein 
labeling is kept relatively low. 
3.2 Materials and Methods 
3.2.1 Materials 
The maltose binding protein (MBP) was obtained from MyBioSource.com (San 
Diego, CA). Human full-length β-2-microglobulin (β2m) was purchased from Lee 
Biosolutions (Maryland Heights, MO). Lysozyme from chicken egg white and the 
following chemicals were obtained from MilliporeSigma (St.Louis, MO): DL-
dithiothreitol (DTT), diethylpyrocarbonate (DEPC), dimethyl(2-hydroxy-5-
nitrobenzyl)sulfonium bromide (HNSB), epigallocatechin gallate (EGCG), guanidine 
hydrochloride (GuHCL), imidazole, iodoacetamide, maltose monohydrate, MOPS, 
MOPS sodium salt, N,N’,N’’ triacetylchitotriose (NAG3), L-tryptophan, and urea. 
Acetonitrile, copper sulfate (CuSO4), formic acid, potassium acetate, sodium phosphate, 
sodium phosphate monobasic monohydrate, HPLC grade water, and a 1 M Tris buffer 
(pH 8) stock solution were all purchased from Fisher Scientific (Fair Lawn, NJ). 
Centricon molecular weight cutoff (MWCO) filters were obtained from Millipore 
(Burlington, MA). Sequencing grade modified trypsin and sequencing grade 
chymotrypsin were obtained from Promega (Madison, WI). 
3.2.2 Sample Preparation 
Samples containing 30 µM lysozyme were prepared in a 20 mM MOPS (pH 7.4) 
buffer, and stock solutions of NAG3, which binds lysozyme, were prepared in HPLC 
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grade water. Samples containing 24 µM MBP were prepared in 20 mM sodium 
phosphate buffer (pH 7.5), and stock solutions of maltose were prepared in the same 
buffer. Samples containing 30 µM β2m were prepared in 25 mM MOPS buffer (pH 7.4), 
60 µM Cu(II) (CuSO4), 500 mM urea, and 200 mM potassium acetate. EGCG stock 
solutions were prepared in water. Different concentrations of the small molecule ligands 
were mixed with the corresponding protein to conduct the titration experiments. All 
samples were equilibrated at room temperature (22 °C) for 2 to 5 min after the protein 
was mixed with the ligand and before performing the CL reactions. 
3.2.3 HNSB Labeling 
HNSB stock solutions were prepared in water. The reaction was initiated by 
adding an aliquot of the HNSB stock solution to the buffered protein-ligand sample, was 
allowed to proceed at room temperature, and then was quenched by adding tryptophan to 
a concentration of 5 mM. The concentration of HNSB and reaction times were varied to 
examine the effect of different labeling extents on the measured Kd values. 
3.2.4 DEPC Labeling 
DEPC stock solutions were freshly prepared in acetonitrile for each experiment. 
The reaction was initiated by adding an aliquot of the DEPC stock solution to the 
buffered protein-ligand sample, with the final DEPC concentration depending on the 
protein and the experiment. The final volume percentage of acetonitrile was less than 1% 
in all experiments. The reaction was allowed to proceed at 37 °C for 1 min, before being 
quenched by the addition of imidazole at a final concentration of 10 mM. These labeling 
conditions are similar to our group’s previous studies with this CL reagent [23, 26]. 
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3.2.5 Proteolytic Digestion 
CL-modified proteins that were subjected to proteolytic digestion and LC/MS/MS 
analysis were prepared by the following procedure. Before denaturing the protein, 
samples were diluted with water to a volume of 400 μL and then concentrated using a 
10,000 MWCO filter to a final volume of 40 μL. Samples containing MBP were 
reconstituted with 0.25 M Tris (pH 8.0) and 6 M GuHCL to the final volume of 100 μL. 
After incubating at 55 °C for 1 h to denature the protein, the samples were allowed to 
cool before being diluted again by 300 μL of water. Then, the samples were concentrated 
by a 10,000 MWCO filter to a final volume of 40 μL. The dilute-concentrate procedures 
were repeated one more time to reduce the concentration of GuHCL and increase the 
concentration of the protein. The 40 μL samples were then reconstituted in a 0.1 M Tris 
(pH 8.0) buffer and digested by trypsin for 2 h at 37 °C if the protein was HNSB labeled, 
or by chymotrypsin digestion for 2 h at 25 °C if the protein was DEPC labeled. 
The samples containing β2m were reconstituted with 0.25 M Tris (pH 8.0), 
acetonitrile, and 1 M of a freshly prepared DTT stock solution to a final concentration of 
0.1 M Tris, 13% (v/v) acetonitrile and 10 mM DTT. After incubating at 55 °C for 1 h, the 
sample was allowed to cool, and the reduced disulfide bond was alkylated by 14 mM 
iodoacetamide (prepared in 0.25 M Tris buffer, pH 8.0) in the dark at room temperature 
for 15 min. The denatured and reduced protein was then digested by chymotrypsin for 2 h 
at 25 °C.  
3.2.6 Liquid Chromatography−Mass Spectrometry (LC/MS) 
For intact protein analyses, measurements were performed on a Bruker (Billerica, 
MA) AmaZon quadrupole ion trap mass spectrometer equipped with an electrospray 
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ionization source. Typically, the electrospray needle voltage was kept at ∼4 kV, and the 
capillary temperature was set at 220 °C. HPLC separations were performed using a 
Thermo Scientific (Waltham, MA) Ultimate 3000 HPLC with an OPTI-TRAP MICRO 
column (1 mm x 12 mm, Optimize Technologies Inc., Oregon City, OR). The proteins 
were eluted using a gradient of acetonitrile containing 0.1% formic acid that increased 
from 5 to 99% for 10 min at the flow rate of 50 µL/min. 
For peptide mixture analyses, measurements were performed on a Thermo 
Scientific Orbitrap Fusion mass spectrometer equipped with a nano-electrospray 
ionization source. The needle voltage was set at 2.1 kV, and the ion transfer tube 
temperature was set at 325 °C. The resolution of the Orbitrap was set at 60,000, the MS1 
AGC target was set at 4 × 105 ions with a maximum injection time of 50 ms. Collision-
induced dissociation (CID) with a normalized collision energy of 35% was used for 
tandem mass spectrometry (MS/MS). Data-dependent selection for precursor ions with 
ion abundances above 5,000 was used, and a dynamic exclusion of 30 s was activated 
after 3 spectra were acquired for any given precursor ion within 5 s. The MS/MS AGC 
target and maximum injection time were set to 5 × 104 ions and 100 ms, respectively. 
HPLC separations were conducted by a Thermo Scientific Easy-NanoLC 1000 system 
with a Thermo Scientific Acclaim PepMap C18 nanocolumn (15 cm x 75 μm ID, 2 μm, 
100 Å). Peptides were eluted using a gradient of acetonitrile containing 0.1% formic acid 
that increased from 0 to 50% for 60 min at the flow rate of 0.3 µL/min. 
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3.2.7 Determination of Covalent Labeling Modification Percentages 
Residue level CL modification percentages (% labeling) were calculated by 
integrating the peak area of eluting peptides (i.e., modified or unmodified) using 
extracted ion chromatograms. The % labeling was calculated based on eq 1.  
 
% labeling =
∑ ∑ 𝐴𝑖,𝑧
𝑚𝑜𝑑𝑖𝑓𝑖𝑒𝑑𝑚
𝑧=1
𝑛
𝑖=1
∑ ∑ 𝐴𝑖,𝑧
𝑚𝑜𝑑𝑖𝑓𝑖𝑒𝑑
+∑ ∑ 𝐴𝑖,𝑧
𝑢𝑛𝑚𝑜𝑑𝑖𝑓𝑖𝑒𝑑𝑚
𝑧=1
𝑛
𝑖=1
𝑚
𝑧=1
𝑛
𝑖=1
 × 100           (1) 
 
Ai,z represents the peak area of the peptide of interest. Peak areas from all of the 
measurable peptides (i) that contain the residue of interest and all detectable charge states 
(z) are included. The determined modification percentages are relative rather than 
absolute values because the modified and unmodified peptides have different ionization 
efficiencies and LC elution times.  
To determine intact protein CL modification percentages, the calculation is 
similar but simplified. Averaged ion abundances during protein elution were used instead 
(eq 2), and the ion abundance of multiple charge states were summed.  
 
% labeling =
∑ 𝐼𝑚𝑜𝑑𝑖𝑓𝑖𝑒𝑑𝑧
∑ 𝐼𝑚𝑜𝑑𝑖𝑓𝑖𝑒𝑑𝑧 +∑ 𝐼𝑢𝑛𝑚𝑜𝑑𝑖𝑓𝑖𝑒𝑑𝑧
 × 100   (2)       
 
In determining whether two labeling results were different, an unpaired student t-
test was applied with a 99% confidence interval.  
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3.2.8 Calculation of Kd 
In this work, we focus on the most frequently encountered case where only one 
ligand (L) binds to one protein (P), and only one kind of protein-ligand complex (PL) is 
formed. The dissociation constant (Kd) in such a system can be described by eq 3. 
𝑲𝒅 =
[𝑷][𝑳]
[𝑷𝑳]
                 (3) 
where [P], [L], and [PL] are the equilibrium concentrations of P, L, and the 
complex PL, respectively. The total concentration of ligand ([L]0) and protein ([P]0) has 
the following concentration relationship with related fractions in the system, respectively 
(eq 4 and 5):  
 
[𝑳]𝟎 = [𝑳] + [𝑷𝑳]         (4) 
[𝑷]𝟎 = [𝑷] + [𝑷𝑳]        (5) 
 
Because ligand binding decreases the extent of labeling of the residues at the 
binding interface, we assume there is a relationship between the covalent labeling result 
(represented by % labeling) and the concentration of ligand-free protein in the system 
([P]). This relationship can be normalized to the extent of labeling when the protein is 
100% bound to the ligand (i.e. maximum ligand) and when no ligand is present. The 
resulting relationship is represented by eq 6:  
 
[𝑷]
[𝑷]𝟎
=
∆%𝒍𝒂𝒃𝒆𝒍𝒊𝒏𝒈
%𝒍𝒂𝒃𝒆𝒍𝒊𝒏𝒈𝒎𝒂𝒙𝒊𝒎𝒖𝒏 𝒍𝒊𝒈𝒂𝒏𝒅−%𝒍𝒂𝒃𝒆𝒍𝒊𝒏𝒈 𝒏𝒐 𝒍𝒊𝒈𝒂𝒏𝒅
    (6) 
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By combining equations 3-6, the following relationship that relates the relative 
change in labeling to Kd in terms that include the total ligand and protein concentrations 
(eq 7) can be derived.  
 
𝑟𝑒𝑙𝑎𝑡𝑖𝑣𝑒 𝑚𝑜𝑑𝑖𝑓𝑖𝑐𝑎𝑡𝑖𝑜𝑛 𝑓𝑟𝑎𝑐𝑡𝑖𝑜𝑛𝑎𝑙 𝑐ℎ𝑎𝑛𝑔𝑒
=
∆%𝑙𝑎𝑏𝑒𝑙𝑖𝑛𝑔
%𝑙𝑎𝑏𝑒𝑙𝑖𝑛𝑔𝑚𝑎𝑥𝑖𝑚𝑢𝑛 𝑙𝑖𝑔𝑎𝑛𝑑 − %𝑙𝑎𝑏𝑒𝑙𝑖𝑛𝑔 𝑛𝑜 𝑙𝑖𝑔𝑎𝑛𝑑
 
= (([𝐿]0 + [𝑃]0 + 𝐾𝑑) − (([𝐿]0 + [𝑃]0 + 𝐾𝑑)
2 − 4 × [𝑃]0 × [[𝐿]0])
0.5)/2[𝑃]0     
(7)  
A plot of the relative modification fractional change, based on labeling percentage 
measurements, as a function of total ligand concentration used during the titration 
experiments can be used to determine Kd. Fitting of eq 7 was performed using a 
customized non-linear curve fit in Origin 8 (OriginLab Corporation, Northampton, MA). 
The results from each experimental replicate were fit individually, then an averaged Kd 
value from three experiment replicates is reported. 
3.2.9 Solvent Accessible Surface Area (SASA) Calculations 
Solvent accessible surface area (SASA) was calculated using GETAREA [27]. A 
protein’s structure file in PDB format was used for calculation. Radius of the water probe 
was set at 1.4 Å with no gradient in calculation applied. The acquired SASA percentage 
is the ratio of side-chain surface area to "random coil" value per residue. The "random 
coil" value of a residue X is the average solvent-accessible surface area of X in the 
tripeptide Gly-X-Gly in an ensemble of 30 random conformations. SASA (%) range from 
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0 to 100%. Generally, a residue is considered to be solvent exposed if the ratio value 
exceeds 50% and to be buried if the ratio is less than 20%. 
3.3 Results and Discussion 
3.3.1 Effect of Labeling Extent on the Apparent Kd Value 
We predict that CL/MS based on slow labeling reactions is capable of 
determining the Kd values of a protein-ligand complex as long as the overall fraction of 
labeled protein is kept at low levels such that the perturbation to the equilibrium is 
limited. To illustrate this idea, consider a hypothetical protein-ligand system with a Kd 
value of 10 µM (Kd1) that upon CL of the free protein results in a significantly weaker 
interaction with the ligand and a new Kd value of 1000 µM (Kd2). The concentration 
relationship between each fraction in the system can be described by equations 8-11, 
where [L] is the free ligand concentration at equilibrium, [P] is the unlabeled protein 
concentration, [P’] is the labeled protein concentration, [PL] is the concentration of the 
unlabeled protein-ligand complex, [P’L] is the concentration of the labeled protein-ligand 
complex, [L0] is total ligand concentration, and [P0] is the initial total protein 
concentration.  
[𝐿] + [𝑃𝐿] + [𝑃′𝐿] = [𝐿0]  (8) 
[𝑃] + [𝑃′] + [𝑃𝐿] + [𝑃′𝐿] = [𝑃0] (9) 
𝐾𝑑1 =
[𝑃][𝐿]
[𝑃𝐿]
 (10) 
𝐾𝑑2 =
[𝑃′][𝐿]
[𝑃′𝐿]
 (11) 
If one considers the percentage of the labeled protein as described in eq 12, then 
the apparent Kd will be defined by eq 13. 
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% labeling =
[𝑃′]+[𝑃′𝐿]
[𝑃0]
 (12) 
𝐴𝑝𝑝 𝐾𝑑 =
[𝑃+𝑃′]×[𝐿]
[𝑃′𝐿+𝑃𝐿]
 (13) 
The relationship between the apparent Kd and the percent labeling can then be 
plotted for any labeling extent between 0 and 100% (Figure 3.1). Not surprisingly, when 
there is no labeling, the apparent Kd is equal to the real Kd (i.e. 10 µM in this hypothetical 
situation), whereas at 100% labeling the apparent Kd is equal to the Kd of the more 
weakly binding labeled protein (i.e. 1000 µM in this hypothetical situation). More 
interestingly is the observation that when the percent labeling is kept low (e.g. below 
30%), the apparent Kd differs from the real Kd by less than a factor of 2, meaning that as 
long as the extent of labeling is kept low, reasonably accurate Kd values can be obtained. 
It should be pointed out that often the variation in measured Kd values for protein-ligand 
complexes differ by more than a factor of 2 when different measurement methods are 
compared [28]. Of course, if the percent labeling is much higher (e.g. above 70%), the 
apparent Kd value is 1 or more orders of magnitude higher than the real Kd value, which is 
typically unacceptably inaccurate. 
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Figure 3.1 Relationship between apparent Kd and real Kd explained by a 
hypothetical model. 
When %labeling is controlled below 50%, apparent Kd is within 5-fold range of actual Kd. 
3.3.2 Lysozyme-NAG3 Binding 
To test our hypothesis, the first model system we selected was the NAG3-
lysozyme complex. Because the NAG3 binding site includes two Trp residues, Trp62 and 
Trp63 [29, 30], we used HNSB, which is a Trp-specific labeling reagent. Reactions of 
HNSB with lysozyme with and without NAG3 result in only Trp62 being labeled as 
indicated by LC/MS/MS data (Figure3.2), as the solvent accessible surface area (SASA) 
of Trp63 is very low. Because only Trp62 is labeled, the labeling ratio of the intact 
protein could be used during the ligand titration experiments. 
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Figure 3.2 Identify Trp62 of lysozyme modified by HNSB. 
Lysozyme surface structure with the (NAG)3 binding site shown from PDB 1HEW. 
Trp62 is indicated in blue, and (NAG)3 is in orange. Tandem mass spectrum of the 
peptide 54GILQINSRWW63 from lysozyme. The tandem mass spectrum indicates that 
W62 is modified by HNSB. 
 
To determine the Kd value using CL/MS, a titration curve was generated in which 
the NAG3 concentration was varied between 0 and 600 µM at a fixed lysozyme 
concentration of 30 μM. HNSB was added at a concentration of 1.5 mM and allowed to 
react with the protein for 10 s. This titration experiment resulted in a decrease in the 
percent labeling with increased total ligand concentration (Figure 3.3.1). As expected, 
increasing NAG3 concentrations lead to more protein molecules in which Trp62 is 
protected from labeling, leading to an overall decrease in the overall percent labeling. 
The HNSB labeling data were then plotted and fit using eq 7 (Figure 3.3.2), and a Kd of 
14 ± 2 μM is obtained. Previous measurements of the lysozyme-NAG3 Kd by methods 
such as fluorescence, UV, and ESI-MS resulted in values that range from 6 - 60 μM [28, 
31-35]. Clearly, our CL approach is able to provide a value that is consistent with prior 
studies. 
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Figure 3.3 HNSB covalent labeling of lysozyme in the presence of (NAG)3 using a 
1.5 mM concentration of HNSB and 10 s reaction time. 
(1) HNSB covalent labeling percentage of lysozyme as a function of (NAG)3 
concentrations. (2) HNSB labeling results fit using equation 7, resulting in a lysozyme-
(NAG)3 Kd of 14 ± 2 μM. 
 
 
To investigate if the CL modification extent significantly perturbs the ligand-
binding equilibration (leading to variations in the apparent Kd), additional HNSB labeling 
conditions were explored in the context of the same titration experiment. Labeling with 
1.5 mM HNSB for 30 s and 0.75 mM HNSB for 10 s resulted in more and less extensive 
labeling, respectively, than the conditions used to generate Figure 3.3.1. These resulting 
titration curves are shown in Figure 3.4.1, and the corresponding fits to eq 7 are shown in 
Figure 3.4.2 and 3.4.3. Comparing the Kd results from the three labeling conditions, the 
results are not significantly different from each other at 95% confidence interval. 
Moreover, there is no clear trend in the Kd value with the extent of labeling, indicating 
that the labeling extent does not have a strong influence on the resulting Kd value. The 
reason for this is likely the fact that the extent of the protein labeling at higher ligand 
concentrations is very low (< 10% for almost all ligand concentrations), resulting in very 
minimal perturbation to the protein-ligand binding equilibrium. 
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(1)  
(2) (3) 
  
 
Figure 3.4 HNSB covalent labeling of lysozyme in the presence of (NAG)3 at 
different extents of labeling. 
 (1) HNSB labeling extent for lysozyme at three different labeling conditions as a 
function of (NAG)3 concentration. (2) HNSB labeling at 1.5 mM HNSB and a 30 s 
reaction time fit to equation 7, resulting in a lysozyme-(NAG)3 Kd of 19 ± 2 μM. (3) 
HNSB labeling at 0.75 mM HNSB and a 10 s reaction time fit to equation 7, resulting in 
a lysozyme-(NAG)3 Kd of 17 ± 4 μM. 
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(1) 
 
(2) 
 
 
Figure 3.5 CL for determining significantly changed residues of MBP. 
 (1) Bar graph summarizing the labeling ratio of no ligand and with 285 μM maltose. (2) 
Surface structure of MBP in the ligand-free “open” state (PDB 1OMP) and the ligand-
bound “closed” state (PDB 1ANF). The two residues with significantly decreased 
labeling ratio, Lys297 and Trp340 in blue. 
3.3.3 Kd of Maltose to Maltose Binding Protein 
The second model system that we investigated was the maltose binding protein 
(MBP) bound to maltose. This system allowed us to investigate if accurate Kd values can 
be acquired by using the extent of labeling at multiple residues. Both HNSB and DEPC 
were used to label the protein, and upon comparing MBP labeling in the presence and 
absence of maltose, we find that Trp340 from the HNSB labeling and Lys297 from the 
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DEPC labeling show statistically significant decreases upon ligand binding (Figure 3.5). 
These residues are expected to decrease in labeling because based on the crystal 
structures for the protein and its complex with maltose, their SASA values all decrease 
upon ligand binding [36]. Trp230’s SASA also decreases upon ligand binding and is 
labeled extensively by HNSB, but the extent of labeling on this residue varied 
considerably as the maltose concentration was increased. (Table 3.1) 
Separate titrations were conducted with HNSB labeling and DEPC labeling with a 
fixed MBP concentration of 24 µM, while the concentration of maltose was varied from 0 
to 285 µM (Figure 3.6 and 3.7). As was observed for the lysozyme-NAG3 system, the 
extents of labeling at Trp340 and Lys297 decrease as the maltose concentration is 
increased, although because the MBP measurements are from peptide fragments after 
digestion and LC/MS, the errors are larger than observed for the lysozyme system (Figure 
3.6.1 and 3.6.3). From the HNSB labeling data of Trp340, a Kd value of 7 ± 4 µM is 
obtained (Figure 3.6.2). This value is comparable to a Kd value of 1 to 3 µM that was 
measured previously by fluorescence [37-40]. Interestingly, other Trp residues (e.g. Trp6, 
Trp10, Trp94, Trp129, Trp158, and Trp232) that are distant from the binding site or do 
not change in SASA upon ligand binding (Table 3.1) do not undergo any significant 
change in labeling extent. As examples, Trp10 and Trp158 are modified by HNSB, but 
because these residues are distant from the ligand binding site, their extents of labeling do 
not change as the maltose concentration is increased (Figure 3.7.1 and 3.7.2). Residues 
like Trp10 and Trp158 serve as useful controls for residues like Trp340 that undergo 
changes in labeling upon ligand binding. 
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Table 3.1 SASA value of CL modified residues of MBP. 
Residue No ligand 
PDB 1OMP (%) 
With ligand 
PDB 1ANF (%) 
K1 Unresolved in the 
crystal structure 
Unresolved in the 
crystal structure 
W10 11.9 10.6 
K25 54.2 83.4 
K26 67 64.7 
W62 22.5 22.7 
K83 96 94.1 
K88 63.1 57.8 
W94 3.8 3.6 
K102 67.1 66.3 
K119 48.3 47.1 
K127 64.6 83.8 
W129 0.3 1.1 
K140 46.2 43.2 
K142 62.5 48.5 
K144 35.2 30.6 
W158 0.1 1.4 
K179 62.3 68.9 
K189 30.5 39.9 
K200 67.2 62.2 
K202 68.3 79.9 
H203 15.7 16.4 
W230 34.3 5.2 
W232 10.3 1.2 
K239 87.3 82.1 
K251 48.6 56.6 
K256 26.5 30.8 
K273 43.7 44.7 
K295 69.6 67.1 
K297 38 23.9 
K305 61.5 47 
K313 87.8 71.7 
W340 25 7.1 
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(1) (2) 
  
(3) (4) 
  
 
Figure 3.6 CL for determining Kd of MBP and maltose. 
(1) HNSB labeling extent of Trp340 in MBP as a function of maltose concentration. (2) 
HNSB labeling results for Trp340 fit using equation 7, resulting in a MBP-maltose Kd of 
7 ± 4 μM. (3) DEPC labeling extent of Lys297 in MBP as a function of maltose 
concentration. (4) DEPC labeling results for Lys297 fit using equation 7, resulting in a 
MBP-maltose Kd of 4 ± 4 μM. 
 
 
We also explored titrations with DEPC because it is a labeling reagent that can 
modify up to six different types of amino acids, including Lys, His, Tyr, Ser, Thr, and 
Cys residues [14]. Even though DEPC can label so many residues, only Lys297 
undergoes a significant decrease in labeling extent in the presence of maltose. Indeed, of 
the 25 residues in MBP that can be labeled by DEPC, Lys297 undergoes the greatest 
percent change in SASA value (from 38% to 23%) upon maltose binding. Upon plotting 
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the labeling data for Lys297, a Kd value of 4 ± 2 µM is obtained (Figure 3.6.4). This 
value is similar to the value obtained from HNSB labeling of Trp340 and is comparable 
to the literature value for the MBP-maltose complex [37-40]. It is worth noting that the 
data for Lys297 provides a reasonable measure of the Kd even though it is not a residue 
directly interacting with maltose. This observation demonstrates that residues in regions 
that undergo a structural change upon ligand binding can also be applied for Kd 
determination. Several other residues, such as Lys26, Lys239, and Lys295 (Figure 3.7.3), 
undergo no change in labeling upon maltose binding, and thus serve as useful controls. 
Like the HNSB labeling experiments of the NAG3-lysozyme complex, the low 
extent of labeling observed at MBP residues that undergo changes in SASA (i.e. Trp340 
and Lys297) upon ligand binding facilitates determination of a Kd value that is close to 
the literature value. In the case of MBP, the extents labeling of Trp340 and Lys297 are 
below 25% and 0.5%, respectively. Because labeling by both HNSB and DEPC is limited 
to about one label on average per protein molecule, which is spread across multiple 
modifiable residues all over the protein, the extent of modification at any given residue, 
including binding residues, is low (see Figure 3.5.1). Thus, the number of modified 
protein molecules that might perturb the protein-ligand equilibrium is expected to be low.  
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(1) 
(2) (3) 
  
 
Figure 3.7 Example residues that do not have clear trend in labeling ratio with 
increasing concentration of maltose. 
(1)Showing the location of selected residues on MBP-maltose surface structure (PDB 
1ANF), residues with significantly decreased labeling ratio are in blue, no significant 
change in cyan. Labeling ratio of Trp10 and Trp158 (2); Lys26, Lys239, and Lys295 (3), 
do not have clear trend in increasing concentration of maltose. 
 
3.3.4 Kd of EGCG to β2m 
We next applied CL/MS to determine the Kd for epigallocatechin gallate (EGCG) 
bound to β-2-microglobulin (β2m). β2m forms amyloid fibrils in patients who undergo 
long term dialysis due to kidney failure [41], and EGCG (Figure 3.8.1) has recently been 
found by our group to prevent Cu(II)-induced β2m amyloid formation in vitro by 
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redirecting β2m aggregation toward amorphous, re-dissolvable aggregates [42]. Thus, we 
decided to apply a CL-MS based method to determine the Kd of this complex.  
EGCG concentrations ranging from 0 to 115 μM and a β2m concentration of 30 
μM were used in a titration experiment along with DEPC labeling. DEPC labeling at high 
EGCG concentrations indicate that several residues undergo both increased and 
decreased extents of labeling upon ligand binding, including the N-terminal amine, Thr4, 
Lys6, His13, His31, and Lys91 (Figure 3.8.2). Most of these residues, particularly the 
ones that decrease in labeling extent, are near the N-terminus region of the protein 
(Figure 3.8.3), suggesting EGCG’s binding site is between one β sheet that includes 
residues from Lys6 to Ser11 and another that includes residues from Lys91 to Asp96.  
Interestingly, some of the residues that undergo increased labeling, specifically 
the N-terminal amine and His31, are residues that comprise the Cu(II) binding site in the 
Cu(II)-β2m complex [43, 44]. The increased reactivity of these residues with DEPC as 
the EGCG concentration is increased suggests that EGCG is disrupting the Cu(II) binding 
site to some extent. Indeed, the Kd of the Cu(II)-β2m complex increases from 3.3 μM to 
49 μM in the presence of EGCG (Figure 3.9), which decreases the concentration of the 
β2m-Cu(II) complex. The reduced concentration of the metal-bound protein means that 
when EGCG is present the N-terminus and His31 are free in more protein molecules to 
react with DEPC.  
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Figure 3.8 EGCG binding to Cu(II)-β2m results in decreases and increases in DEPC 
labeling at several residues. 
 (1) Structure of EGCG. (2) DEPC labeling results of Cu(II)-β2m. (3) Residues 
undergoing covalent labeling with DEPC mapped onto the Cu(II)-free structure of β2m 
(PDB 1JNJ). Note that there is no structure is available for Cu(II)-β2m. DEPC modified 
residues that undergo no significant change upon ligand binding are shown in cyan. 
Those residues that decrease or increase in labeling extent are shown in blue and red, 
respectively. The proposed EGCG binding site is indicated by the black circle. 
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Figure 3.9 Fluorescence spectroscopy determining Cu(II) binding to β2m. 
Intrinsic fluorescence of β2m indicating Cu(II) binding affinity (as Kd) to β2m monomer. 
Ligand absent in the black line, with EGCG in the red line. 
 
DEPC labeling as a function of EGCG concentration for residues that both 
increase and decrease in labeling in the presence of EGCG are shown in Figure 3.10.1. 
The Kd acquired from the labeling results of the N-terminal amine, Lys6, and Lys91 are 
12 ± 5 µM, 3.2 ± 3 µM, and 11 ± 5 µM, respectively (Figure 3.10.2, 3.10.3, and 3.10.4). 
These values are reasonably similar, and they indicate an EGCG-β2m Kd value of 
between 3 and 12 µM. It is interesting to note that although the increase in the labeling of 
the N-terminal amine is likely due to the release of Cu(II) caused by ligand binding, the 
resulting value is consistent with the Kd value obtained from the residues that are 
protected from DEPC labeling. The Kd values acquired by CL-MS are also consistent 
with the Kd value of 6 µM obtained from size exclusion chromatography data (Figure 
3.11) [42]. 
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(3) (4) 
 
 
 
Figure 3.10 Selected residues in Cu(II)-β2m for determining Kd of EGCG to the 
protein. 
(1) DEPC labeling extent of N-terminus, Lys6, and Lys91 in Cu(II)-β2m as a function of 
EGCG concentration. (2) DEPC labeling results for N-terminus fit using equation 7, 
resulting in a Cu(II)-β2m and EGCG Kd of 12 ± 5 μM. (3) DEPC labeling results for 
Lys6 fit using equation 7, resulting in a Cu(II)-β2m and EGCG Kd of 3.2 ± 3 μM. (4) 
DEPC labeling results for Lys91 fit using equation 7, resulting in a Cu(II)-β2m and 
EGCG Kd of 11 ± 5 μM. 
 
 
0 20 40 60 80 100 120
0
5
10
15
20
25
30
35
40
45
50
55
%
 l
a
b
e
lin
g
[EGCG]
0
 M
 Lys91
 Lys6
 N-terminus
0 20 40 60 80 100 120
0.0
0.2
0.4
0.6
0.8
1.0
K
d
 = 12 ± 5 M
R
e
la
ti
v
e
 m
o
d
if
ic
a
ti
o
n
 f
ra
c
ti
o
n
a
l 
c
h
a
n
g
e
[EGCG]
0
 M
0 20 40 60 80 100 120
0.0
0.2
0.4
0.6
0.8
1.0
K
d
 = 12 ± 5 M
R
e
la
ti
v
e
 m
o
d
if
ic
a
ti
o
n
 f
ra
c
ti
o
n
a
l 
c
h
a
n
g
e
[EGCG]
0
 M 0 20 40 60 80 100 120
0.0
0.2
0.4
0.6
0.8
1.0
K
d
 = 11 ± 5 M
R
e
la
ti
v
e
 m
o
d
if
ic
a
ti
o
n
 f
ra
c
ti
o
n
a
l 
c
h
a
n
g
e
[EGCG]
0
 M
  86 
 
Figure 3.11 Peak heights from SEC chromatography to determine Kd of EGCG to 
β2m. 
SEC-HPLC data was collected on an Agilent 1100 series HPLC that was outfitted with a 
SuperSW2000 column purchased from Tosoh Bioscience (Tokyo, Japan). The mobile 
phase consisted of 150 mM ammonium acetate. The flow rate was 0.35 mL/min. The 
detector was set to 214 nm. “Response” is the normalized data from relative peak heights, 
M*/M. Where M represent β2m monomer. M* represent intermediate peak that appears 
to elute between the dimer and monomer peaks, which can be used to represent EGCG 
bound Cu(II)-β2m. 
 
3.4 Conclusion 
We have demonstrated that CL-MS can be used to obtain reasonably accurate Kd 
values for protein-ligand complexes. In particular, we find that reagents like DEPC and 
HNSB can provide this information even when labeling from these reagents might be 
expected to perturb the equilibrium of the protein-ligand complex. We find that accurate 
Kd values can be obtained when the extent of protein labeling is kept low. The 
experimental results from two model systems and one unknown system support this 
conclusion and show that our CL-MS based strategy is able to correctly determine the 
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protein-ligand binding affinity. An intriguing prospect of using CL-MS to determine Kd 
values is the ability to simultaneously identify the ligand binding site, if the residue level 
labeling results contain sufficiently detailed information. This CL-MS based ligand 
titration strategy might serve as an alternative for characterizing protein-ligand 
complexes that are hard to measure by some other methods, such as fluorescence 
spectroscopy, surface plasmon resonance spectroscopy, or nuclear magnetic resonance 
spectroscopy. 
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SYNERGISTIC STRUCTURAL INFORMATION FROM COVALENT 
LABELING AND HYDROGEN-DEUTERIUM EXCHANGE MASS 
SPECTROMETRY FOR PROTEIN-LIGAND INTERACTIONS  
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Covalent Labeling and Hydrogen-Deuterium Exchange Mass Spectrometry for Protein-
Ligand Interactions.  
Analytical Chemistry, manuscript under review  
 
L.P. processed the data of covalent labeling using the custom software pipeline; L.T. 
conducted all the rest experiments. 
4.1 Introduction 
Protein-ligand interactions are fundamental in all living organisms. Understanding 
the details of protein-ligand interactions is an important step for understanding biology at 
the molecular level [1]. Characterizing protein-ligand binding sites as well as ligand 
binding induced structural changes can facilitate drug discovery, design, and 
development [2]. 
Mass spectrometry (MS) based methods have some inherent advantages for 
studying protein-ligand interactions over other methods that reveal a protein’s higher 
order structure (HOS) such as X-ray crystallography and NMR [3]. These advantages 
include limited sample consumption, almost no protein size limitations, and the ability to 
obtain information in mixtures. As a result of these advantages, many MS-based methods 
have been explored to study protein-ligand interactions to characterize binding 
stoichiometries, binding constants, and binding sites [4-7]. 
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Hydrogen deuterium exchange (HDX) MS is a well-established method to study 
protein’s HOS that is increasingly used in the pharmaceutical industry [8-10]. HDX relies 
on changes in mass resulting from backbone amide hydrogen exchange with deuterium at 
rates that vary based on a number of factors, including protein secondary structure, 
solvent accessibility, pH, and temperature. For a backbone amide hydrogen in an 
unstructured region of the protein in a solution at neutral pH, the intrinsic exchange rate 
is on the order of milliseconds [11]. However, in a folded protein this exchange rate can 
vary significantly from minutes to days as a result of the sequence, structure of the 
protein, accessibility of a given region to solvent, and protein backbone dynamics [12]. 
Upon ligand binding to a protein, changes in accessibility to solvent and to protein 
structural fluctuations can occur at the ligand binding site and elsewhere in the structure 
that can protect the protein from exchange [13, 14]. This allows HDX-MS to be a useful 
technique to characterize the protein-ligand binding sites [15-17]. However, it is also 
common that ligand binding can affect overall protein stability and dynamics in other 
structural regions distant from the binding site. This effect can make it difficult to 
distinguish which decreases in HDX result from local protection due to ligand binding 
and which are caused by allosteric effects that lead to distant protection against exchange. 
Covalent labeling (CL) MS is another method that has been used to characterize 
protein-ligand complexes [6, 18-22]. In CL, a labeling reagent is used to modify amino 
acid side chains of the protein by forming a covalent bond [23, 24]. This results in a mass 
shift that can be detected via MS. CL-MS can be used to study protein-ligand interactions 
because ligand binding decreases the solvent accessibility of the side chains involved in 
ligand binding. Decreased labeling at specific residues can be used to determine the 
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ligand binding site. Covalent labeling techniques can be divided into two categories: 
amino acid specific labeling techniques (e.g. Lys-specific labeling) [23] and non-specific 
labeling techniques (e.g. hydroxyl radical footprinting, carbene labeling, and DEPC 
labeling) [24-26]. Non-specific labeling techniques have a range of intrinsic reaction 
rates, ranging from ns for carbene labeling [27, 28] to µsec/ms for hydroxyl radical 
labeling [29] to 10’s of seconds for DEPC labeling [30]. The faster reacting CL reagents, 
such as hydroxyl radicals, are likely sensitive to changes in protein dynamics, whereas 
reagents that react more slowly, such as DEPC, are presumably transparent to protein 
dynamics.  
Because HDX probes backbone amide hydrogens when used with MS and CL 
probes the solvent accessibility of side chains, these two methods are typically considered 
to be complementary. We hypothesize, though, that as a result of the large differences in 
intrinsic reaction rates between HDX and CL reagents like DEPC, the two techniques can 
provide synergistic information regarding structural changes that take place upon ligand 
binding. Ligand binding usually induces a decrease in local solvent accessibility at the 
binding site and often a decrease in protein dynamics at distant sites as proteins are often 
stabilized by interactions with the ligand. Because HDX responds to changes in both 
solvent accessibility and structural fluctuations, it sometimes provides ambiguous 
information with regard to ligand binding site. We predict that the slower labeling 
timescale for DEPC labeling should make it only sensitive to changes in solvent 
accessibility and insensitive to changes in protein dynamics. Thus, when used together, 
HDX and CL have the potential to provide clearer information about protein-ligand 
binding sites and changes in protein dynamics caused by ligand binding. 
  93 
Here, we test this hypothesis by comparing HDX-MS and CL-MS on three model 
protein-ligand complexes. From these experiments we show that when used together the 
two methods provide both complementary and synergistic information about protein-
ligand interactions. 
4.2 Experimental and Methods 
4.2.1 Materials 
Myoglobin from equine skeletal muscle, apomyoglobin from equine skeletal 
muscle and carbonic anhydrase isozyme II from bovine erythrocytes (BCA) were 
purchased from MilliporeSigma (St.Louis, MO). Maltose binding protein (MBP) was 
obtained from MyBioSource.com (San Diego, CA). Brinzolamide, deuterium oxide (99.9 
atom %D), diethylpyrocarbonate (DEPC), dimethyl(2-hydroxy-5-nitrobenzyl)sulfonium 
bromide (HNSB), guanidine hydrochloride (GuHCL), imidazole, maltose monohydrate, 
MOPS, MOPS sodium salt, and L-tryptophan were also purchased from MilliporeSigma. 
Acetonitrile, formic acid, sodium phosphate, sodium phosphate monobasic monohydrate, 
HPLC grade water, and a 1 M Tris buffer (pH 8) stock solution were all purchased from 
Fisher Scientific (Fair Lawn, NJ). Centricon molecular weight cutoff (MWCO) filters 
were obtained from Millipore (Burlington, MA). Sequencing grade modified trypsin and 
sequencing grade chymotrypsin were obtained from Promega (Madison, WI). 
4.2.2 Sample Preparation  
Proteins were prepared in a 20 mM MOPS buffer at pH 7.5 using the material as 
received, except for the maltose-binding protein (MBP). MBP comes from the vendor in 
a 20 mM Tris (pH 8.0) buffer. Before analysis, the buffer was exchanged with a 20 mM 
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phosphate buffer at pH 7.5 using the 10K MWCO filters by several cycles of 
concentration and reconstitution. The concentrations before beginning the CL or HDX 
experiments were 25 or 35 µM for all the proteins. Stock solutions (5 mM) of the 
brinzolamide were prepared in 1:1 (v/v) acetonitrile and water due to the limited water 
solubility of this compound. For experiments involving brinzolamide bound to bovine 
carbonic anhydrase (BCA), the molar ratio between protein and ligand was always 1:1. 
This ratio was sufficient to lead to more than 99% bound, even after dilution for the HDX 
experiments, based on the known Kd of 0.1 nM [31]. The final concentration of 
acetonitrile in the prepared sample was always below 1% (v/v). Maltose stock solutions 
were prepared in 20 mM phosphate buffer, and a maltose concentration of 480 µM was 
used for the maltose-MBP binding experiments. Based on the known MBP-maltose Kd of 
1.5 µM [32], this molar ratio resulted in greater than 99% protein bound during the CL 
experiments and greater than 90% bound during the HDX experiments. 
4.2.3 HDX Experiments 
D2O was prepared in the buffer appropriate for each protein, as indicated above. 
The pD was adjusted via a pH meter corrected by the following relationship: pD = pH 
reading + 0.41 [33, 34]. HDX experiments were conducted using the Leap HDX 
Automation Manager as part of the Waters nanoACQUITY UPLC system (Waters 
Corporation, Milford, MA, USA). The HDX procedure consisted of the following steps: 
To initiate the HDX, 3.8 µL of the prepared protein or protein-ligand complex sample 
was diluted into 52.2 µL D2O buffer and allowed to exchange for different amounts of 
time at 10 °C. At the end of each exchange period, the reaction was quenched by mixing 
the sample with a quenching buffer (1:1, v/v) that contained 3.6 M GuHCl and ~ 0.8% 
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formic acid in water (pH = 2.25) at 1 °C for 1 min. After the quench step, the sample was 
transferred and injected into the Waters ACQUITY UPLC System. Online digestion was 
performed using a Waters ENZYMATE immobilized pepsin column (ID: 2.1 length: 30 
mm). The proteolytic products were collected by a trap column (HSS T3 pre-column, 100 
Å, 1.8 µm, 2.1 mm X 5 mm, Waters) for 4 min. Then, trapped peptides were eluted by a 
Waters ACQUITY C18 column (2.1 x 50 mm, 1.8 µm) at 0 °C with a linear gradient of 
acetonitrile (with 0.1% formic acid) that was increased from 5% to 35% over 7 min and 
then increased from 35% to 85% in 1 min at a flow rate of 40 µL/min. The eluent was 
then directed into a Waters SYNAPT G2Si mass spectrometer for analysis in MSE mode 
over the m/z range of 50 - 2000. The relative deuterium uptake level of each measured 
peptide at different exchange time points was automatically calculated using the DynamX 
3.0 software (Waters). Averaged values from triplicate experiments with propagated error 
are reported. 
Peptides were identified as having statistically significant differences in 
deuterium uptake between ligand-bound and ligand-free states if at least two out of three 
exchange time points (i.e. 10 s, 10 min, and 4 (or 24) h) showed significantly different 
deuterium uptake levels. The 10 s, 10 min, and 4 h (or 24 h) time points were chosen to 
represent short, medium, and long exchange times, respectively. Statistical differences in 
uptake were determined using the following two-step statistical cutoff: 1) a difference in 
deuterium uptake between the ligand bound and ligand free states at a given time point 
was larger than the global deuterium uptake significance limit as described by Hageman 
and Weis [35], the value of which was decided with a 99% confidence interval; and 2) 
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the relative deuterium uptake of the two states at a given time point were significantly 
different from one another according to a Welch’s t-test at a 99% confidence interval.  
4.2.4 CL-MS Experiments 
In all CL experiments, conditions were chosen to control labeling to 1 to 1.5 
labels on average per protein molecule to maintain the structural integrity of the protein 
during the modification reactions [23, 24]. DEPC labeling was performed following 
procedures and conditions previously developed by our group [30, 36]. DEPC stock 
solutions were prepared in acetonitrile. The reaction was initiated by adding an aliquot of 
the DEPC stock solution into the prepared sample. The final concentration of DEPC was 
120 µM for myoglobin, 360 µM for BCA, 300 µM for MBP. The final volume of 
acetonitrile was less than 1% (v/v) in all experiments. The reaction proceeded at 37 °C 
for 1 min and then was quenched by the addition of imidazole at a final concentration of 
10 mM. The HNSB labeling reactions were initiated by adding an aliquot of an HNSB 
solution at 2.7 mM to the prepared sample. The reactions were allowed to proceed at 
room temperature for 3 min before being stopped by the addition of tryptophan at 5 mM. 
After the protein labeling reactions, the samples were diluted with water to a final volume 
of 400 μL and concentrated using a 10,000 MWCO filter to a final volume of 40 μL. 
Then, the samples were reconstituted in 0.25 M Tris (pH 8.0) and 6 M GuHCl at 55 °C 
for 1 h to denature the protein. The samples were then diluted in 300 µL water and 
concentrated again by a 10,000 MWCO filter to volume of 40 µL. This dilution-
concentration step was repeated twice to decrease the GuHCl concentration. The resulting 
sample was diluted to 100 µL with 0.1 M Tris (pH 8.0) buffer and digested with trypsin 
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for 2 h at 37 °C if the protein was HNSB labeled, or with chymotrypsin for 2 h at 25 °C if 
the protein was DEPC labeled. 
The digested proteins were analyzed by LC/MS on a Thermo Scientific 
(Waltham, MA) Orbitrap Fusion mass spectrometer with a nano-electrospray ionization 
source. The electrospray voltage was settled at 2.1 KV and the ion transfer tube 
temperature was set at 325 °C. The resolution of Orbitrap was set at 60,000, the MS1 
AGC target was set at 4 × 105 ions with a maximum injection time of 50 msec. Collision-
induced dissociation (CID) with a normalized collision energy of 35% was used for 
tandem mass spectrometry (MS/MS) experiments. Data-dependent selection of the 
precursor ions with ion abundances above 5,000 was applied. On-line HPLC separation 
of the digested protein samples was conducted using a Thermo Scientific Easy-NanoLC 
1000 system with a Thermo Scientific Acclaim PepMap C18 nanocolumn (15 cm x 75 
μm ID, 2 μm, 100 Å). Peptides were eluted using a gradient of acetonitrile containing 
0.1% formic acid that increased from 0 to 50% for 60 min at the flow rate of 0.3 µL/min. 
For peptide identification and determination of CL extents, a custom software 
pipeline specifically designed for protein CL-MS studies was used [37, 38]. Residue level 
CL modification percentages (% labeling) were determined from the chromatographic 
peak areas of modified and unmodified peptides and by applying eq 1.  
% labeling =
∑ ∑ 𝐴𝑖,𝑧
𝑚𝑜𝑑𝑖𝑓𝑖𝑒𝑑𝑚
𝑧=1
𝑛
𝑖=1
∑ ∑ 𝐴𝑖,𝑧
𝑚𝑜𝑑𝑖𝑓𝑖𝑒𝑑
+∑ ∑ 𝐴𝑖,𝑧
𝑢𝑛𝑚𝑜𝑑𝑖𝑓𝑖𝑒𝑑𝑚
𝑧=1
𝑛
𝑖=1
𝑚
𝑧=1
𝑛
𝑖=1
 × 100           (1) 
In eq 1, Ai,z represents the peptide peak area from any given peptide (i) that 
contains the residue of interest, and considers all detectable charge states (z) for that 
peptide. The resulting modification percentage is a relative rather than an absolute value 
because the modified and unmodified peptides have different ionization efficiencies and 
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elute at different retention times. Unpaired student t-tests with a 99% confidence interval 
were used to determine if a given residue underwent a change in labeling when the ligand 
was present as compared to when the ligand was absent.  
4.3 Results and Discussion 
4.3.1 Myoglobin 
Heme bound and apo myoglobin were selected to test our hypothesis that DEPC 
labeling is insensitive to protein dynamics and thus can provide synergistic information 
when combined with HDX-MS. Apo myoglobin is known to be more dynamic than 
heme-bound myoglobin [39, 40], making myoglobin an excellent model system. 
Comparative HDX-MS measurements of myoglobin and apo-myoglobin result in a large 
number of peptides that undergo a statistically significant change in deuterium uptake 
(Figure 4.1, 4.2, and Table 4.1). These peptides come from four regions of the protein 
that include residues 12-29, 30-69, 70-106, and 137-153. We only observe decreases in 
deuterium uptake upon heme binding and do not observe any peptides that significantly 
increase in deuterium uptake upon ligand binding. Results from HDX/MS indicate that 
heme binding significantly stabilizes the protein, especially in the region spanned by 
residues 30-106, which is consistent with previous studies by NMR [39, 41] and HDX-
MS [40, 42]. Interestingly, exchange decreases are apparent throughout the protein upon 
ligand binding and are not localized to just the ligand binding site. Peptides in the heme-
binding pocket, including parts of residues 30-69 and 70-106, as well as other regions not 
directly involved in the heme-binding site (e.g. 137-153) or even remote from the binding 
pocket (e.g. 12-29) also have significantly decreased deuterium uptake. With the HDX-
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MS data alone, it would be difficult to identify the heme binding site due to the 
widespread stabilization of the protein.  
 
Figure 4.1 Relative fractional deuterium uptake for myoglobin shown on the holo 
myoglobin structure. 
Representative deuterium uptake plots for myoglobin (i.e. with heme) and apo-myoglobin 
(i.e. without heme), and the relative fractional uptake (at the 4 h exchange time point) 
mapped onto the holo myoglobin structure (PDB 1DWR). The darker the blue color on 
the structure, the more the HDX decreases upon heme binding. 
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Figure 4.2 Deuterium uptake plots for myoglobin. 
Myoglobin with heme bound in blue and without heme bound in red. 
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Table 4.1 Peptides from myoglobin with statistically significant differences in the 
relative deuterium uptake. 
Statistically significant differences as determined using the criteria described in 
experimental section. The global deuterium uptake difference significance threshold for 
myoglobin is 1.43 Da. 
Region Sequence position Sequence 
12 – 29 12 – 29 NVWGKVEADIAGHGQEVL 
30 – 69 30 – 53 IRLFTGHPETLEKFDKFKHLKTEA 
30 – 54 IRLFTGHPETLEKFDKFKHLKTEAE 
33 – 69 FTGHPETLEKFDKFKHLKTEAEMKASEDLKKHGTVVL 
54 – 69 EMKASEDLKKHGTVVL 
55 – 69 MKASEDLKKHGTVVL 
70 – 106 70 – 86 TALGGILKKKGHHEAEL 
70 – 103 TALGGILKKKGHHEAELKPLAQSHATKHKIPIKY 
70 – 105 TALGGILKKKGHHEAELKPLAQSHATKHKIPIKYLE 
71 – 86 ALGGILKKKGHHEAEL 
71 – 106 ALGGILKKKGHHEAELKPLAQSHATKHKIPIKYLEF 
72 – 86 LGGILKKKGHHEAEL 
77 – 106 KKKGHHEAELKPLAQSHATKHKIPIKYLEF 
87 – 103 KPLAQSHATKHKIPIKY 
87 – 106 KPLAQSHATKHKIPIKYLEF 
 
Changes in CL-MS with and without the heme are not as widespread throughout 
the protein. Several residues have significant decreases in labeling upon heme binding, 
including T34, K45, K50, T51, K62, H64, S92, H93, T95, K96, H97, K98, and K102 
(Figure 4.3), and these residues are primarily localized around the heme-binding site 
(Figure 4.4). A few of these residues (K50, T51, S58, and K62) are about 12 Å from the 
heme in the bound form. While these residues are not immediately next to the heme, the 
fact that these residues lie in an unstructured loop or in a helix that interacts with the 
heme causes us to surmise that heme binding induces a rearrangement of these side 
chains to change their solvent accessibility.  
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Figure 4.3 DEPC labeling percentages for myoglobin. 
Residues that undergo significant decreases in DEPC labeling at a 99% confidence 
interval are marked with an asterisk “*”. The labeling ratio of Lys145 is 10 ± 4% and 1 ± 
1% without heme and with heme, respectively, and the labeling ratio of Tyr146 is 10 ± 
5% and 0.6 ± 0.2% without heme and with heme, respectively. While these two residues 
show a labeling decrease, they are not significant at the 99% confidence interval that was 
chosen for the rest of the data. 
 
Figure 4.4 Residues of myoglobin identified to undergo significant decreases in 
DEPC labeling upon heme binding. 
Mapping on the holo-myoglobin structure (adapted from PDB 1DWR) the residues 
identified to undergo significant decreases in DEPC labeling upon heme binding (blue). 
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More importantly, there are several protein regions that undergo significant 
decreases in HDX upon heme binding (e.g. 12-29, 71-86, 143-151) (Figure 4.5), but 
show no significant changes in CL. These regions of the protein are stabilized upon heme 
binding, but because they do not directly interact with the heme, they presumably do not 
undergo significant changes in solvent accessibility. Residues 12-29 contain a DEPC-
modified residue, K16; however, this residue does not experience a significant change in 
labeling extent (Figure 4.3). Residues K76, K77, K78, H80, and H81, which all fall 
within region 71-86, are modified by DEPC, but none of them show significant decreases 
in CL (Figure 4.3). While residues 71-86 are part of the larger region of the protein that is 
significantly stabilized by heme binding [39, 40], they do not interact with the heme so 
their solvent exposure likely remains relatively unchanged. A similar result is obtained 
for residues between 143 and 151. Our results and previous HDX-MS results indicate 
protection in this region upon heme binding [40], but the CL changes that K145, Y146 
and K147 undergo are not significant at a 99% confidence interval (Figure 4.3).  
 
Figure 4.5 A comparison of the differential CL and HDX results for myoglobin 
mapped on its crystal structure. 
Regions that undergo significant decreases in HDX upon heme binding are shown in 
green. Residues that undergo significant decreases in DEPC labeling are shown in blue. 
Myoglobin crystal structure: PDB 1DWR. 
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Overall, the myoglobin data support our hypothesis that CL by DEPC is relatively 
insensitive to changes in dynamics as a result of its relatively slow intrinsic reaction rate. 
Residues in protein regions that undergo changes in their transient folding/unfolding (i.e. 
dynamics) do not undergo changes in DEPC reactivity because the reagent reacts too 
slowly to respond to these transient changes in solvent accessibility, whereas HDX is 
sensitive to these changes because the H to D exchange reaction is orders of magnitude 
faster. Heme binding to myoglobin stabilizes the protein, causing several regions (e.g. 12-
29, 71-86, and 143-151) to sample solvent exposed states less frequently (i.e. become less 
dynamic) and thus undergo decreased HDX. These same regions either undergo no 
significant change in solvent accessibility or the lifetimes of these more solvent exposed 
states are too short to allow labeling by DEPC. Because CL by DEPC is primarily 
affected by changes in solvent exposure caused by ligand (i.e. heme) binding, DEPC-
based CL and HDX-MS can provide synergistic structural information. HDX-MS 
indicates regions that are both protected by heme binding and undergo decreased 
structural fluctuations, while CL by DEPC is predominantly sensitive to decreases in 
solvent accessibility. When used together, the techniques provide a more definitive 
picture of the binding site and binding-induced stabilization.  
4.3.2 Bovine Carbonic Anhydrase II 
The second model system we selected was bovine carbonic anhydrase II (BCA) 
and its inhibitor brinzolamide. Extensive studies of human carbonic anhydrase II (HCA) 
indicate that brinzolamide does not cause a significant structural or dynamic change to 
the protein [43, 44]. BCA and HCA have a high degree of sequence and structural 
homology (Figure 4.6), thus brinzolamide binding has a similarly small effect on BCA 
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[43]. This model system provides another test of the complementarity and potential 
synergy of DEPC-based CL and HDX-MS measurements. 
 
Figure 4.6 Overlay of BCA and HCA-brinzolamide structures. 
Overlay of BCA (PDB 1V9E, light brown) and HCA-brinzolamide (PDB 1A42, grey) 
structures with residues interacting with brinzolamide (orange) shown in magenta. 
 
Figure 4.7 Relative fractional deuterium uptake for BCA shown on its structure.  
Representative deuterium uptake plots for BCA and the BCA-brinzolamide complex, and 
the relative fractional uptake (at the 24 h exchange time point) mapped onto the BCA 
crystal structure (PDB 1V9E), with the position of brinzolamide adapted from HCA-
brinzolamide complex (PDB 1A42). The darker the blue color on the structure, the more 
the HDX decreases upon ligand binding. 
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The vast majority of BCA undergoes no significant change in HDX for up to 24 h 
when brinzolamide is bound (Figure 4.7 and 4.8), which is consistent with the known 
effects of ligand binding. However, there is one peptide, 197-203, that undergoes a 
measurable, albeit subtle change in exchange. This peptide contains Thr197, Thr198, and 
Pro202, which are residues known to interact with brinzolamide in the binding pocket of 
the protein [45]. Presumably, the decreased HDX of this peptide is due to decreased 
solvent exposure upon ligand binding. 
When BCA is labeled with DEPC, 19 residues are modified, but only His63, 
Ser64 and Lys259 undergo a significant decrease in labeling in the presence of 
brinzolamide, while Ser28 significantly increases in labeling upon ligand binding (Figure 
4.9). Unfortunately, no labeled residues were measured between residues 197 and 203. 
His63 and Ser64 are on the edge of the brinzolamide binding pocket, so it is not 
surprising that their labeling extent decreases in the presence of the ligand (Figure 
4.10.1). The decreased labeling by Lys259, which is the C-terminal residue, is more 
difficult to explain. Upon brinzolamide binding, this residue reorients itself but does not 
undergo a significant change in SASA. The increased labeling of Ser28 was unexpected 
because its solvent accessible surface area does not change upon ligand binding. One 
possible explanation is that its local microenvironment changes upon brinzolamide 
binding. Ser28 is about 5 Å from Thr198, which interacts with brinzolamide (Figure 
4.10.2). Perhaps the presence of brinzolamide decreases the pKa of the Ser side chain, 
making it more reactive with DEPC. 
 
 
  
  109 
 
 32-47 32-48 34-48 
 IDTKAVVQDPALKPLA IDTKAVVQDPALKPLAL TKAVVQDPALKPLAL 
 
   
35-47  37-43 39-48 40-48 
KAVVQDPALKPLA  VVQDPAL QDPALKPLAL DPALKPLAL 
    
41-48 42-48 50-65  54-65 
PALKPLAL ALKPLAL YGEATSRRMVNNGHSF TSRRMVNNGHSF 
    
55-65 65-78 66-86 69-86 
SRRMVNNGHSF FNVEYDDSQDKAVL NVEYDDSQDKAVLKDGPLT
GT 
YDDSQDKAVLKDGPLTGT 
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KAVLKDGPLTGT KDGPLTGT YRLVQFHFHWGSSDDQGSE VQFHFHWGSSDDQGSE 
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230-239 
NAEGEPELLM 
239-259 
MLANWRPAQPLKNRQVRGFPK 
241-259 
ANWRPAQPLKNRQVRGFPK 
244-259 
RPAQPLKNRQVRGFPK 
    
245-259 
PAQPLKNRQVRGFPK 
   
 
   
 
Figure 4.8 Deuterium uptake plots for BCA. 
BCA with brinzolamide bound in blue and without brinzolamide bound in red. 
 
 
Figure 4.9 DEPC labeling percentages for BCA. 
DEPC labeling results for BCA with (red) and without (white) brinzolamide bound. 
Residues that undergo significant decreases in DEPC labeling at a 99% confidence 
interval are marked with an asterisk “*”. 
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Figure 4.10 DEPC labeling results of BCA on crystal structure. 
(1)Structure of bovine carbonic anhydrase with sites undergoing no change in covalent 
labeling (cyan) or a significant decrease in covalent labeling (blue) with binding site 
residues His63 and Ser64 indicated. (2) Expanded region around the brinzolamide 
binding site in bovine carbonic anhydrase, indicating residues (in magenta) interacting 
with brinzolamide (orange) and the proximity of Ser 28 (red) to the binding residues. 
 
Applying HDX/MS and CL/MS to BCA demonstrates that the two techniques can 
provide complementary information. HDX reveals that the protein undergoes very little 
change in dynamics or structure upon ligand binding, although decreased exchange is 
observed in some parts of the ligand binding site. CL provides complementary insight by 
revealing other regions of the ligand binding site that undergo decreased solvent 
accessibility that are not reported by HDX/MS. Moreover, CL at Ser28 is affected 
indirectly by ligand binding, revealing a subtle change in structure around the binding 
site. 
4.3.3 Maltose Binding Protein 
For a third model system we selected the maltose binding protein (MBP) and its 
ligand maltose, which is known to undergo a conformational change upon ligand binding. 
Two globular domains in MBP are connected by a hinge region that includes a short helix 
(around residues 315-328) and a two-stranded B-sheet (around residues 167-184) [46]. 
These two domains adopt an “open” and “closed” state by a hinge rotation of 35°(Figure 
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4.11) [47-49]. According to previous NMR studies, this conformational change occurs 
with no significant dynamic changes in MBP induced by maltose binding [50]. Such a 
conformational rearrangement with minimal dynamics changes allows this protein-ligand 
system to reveal other aspects of the synergy provided by CL and HDX-MS 
measurements. 
 
Figure 4.11 Structure of ligand free and maltose bound state for the maltose binding 
protein. 
Ligand free “open” state (PDB 1OMP) and maltose bound “closed” state (PDB 1ANF) 
for the maltose binding protein. The residues that are part of the hinge region are 
indicated in magenta. K297 is indicated in blue. 
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Figure 4.12 Relative fractional deuterium uptake for MBP shown on MBP-maltose 
structure. 
Representative deuterium uptake plots for maltose binding protein (MBP) and the MBP-
maltose complex, and the relative fractional uptake (at the 4 h exchange time point) 
mapped onto the MBP-maltose complex crystal structure (PDB ID 1ANF). The darker 
the blue color on the structure, the more the HDX decreases upon ligand binding. 
 
Table 4.2 Peptides from MBP with statistically significant differences in the relative 
deuterium uptake. 
Statistically significant differences as determined using the criteria described in 
experimental section. The global deuterium uptake difference significance threshold for 
MBP is 0.34 Da. 
Region Sequence position Sequence 
8 – 22 
8 – 22 VIWINGDKGYNGLAE 
10– 20 WINGDKGYNGL 
12 – 20 NGDKGYNGL 
13 – 20 GDKGYNGL 
62 – 76 
62 – 70 WAHDRFGGY 
62 – 75 WAHDRFGGYAQSGL 
62 – 76 WAHDRFGGYAQSGLL 
64 – 75 HDRFGGYAQSGL 
322 – 336 322 – 336 ENAQKGEIMPNIPQM 
346 – 361 346 – 361 AVINAASGRQTVDEAL 
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Figure 4.13 Deuterium uptake plots for MBP. 
MBP with maltose bound in blue and without maltose bound in red. 
 
HDX indicates that 10 out of 125 detected peptides (Figure 4.12, 4.13 and Table 
4.2) have a significant decrease in exchange, and these peptides span four regions of the 
protein: 8-22, 62-76, 322-336 and 346-361 (Figure 4.14). The peptides 8-22 and 62-75 
contain residues that line the ligand-binding pocket and form hydrogen bonds with 
maltose [46, 51]. The peptide 322-336 represents part of the hinge region and also has 
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residues that are as close as 4 Å from the maltose binding site. The peptide 346-361 is 
remote from ligand binding site and also is not part of the hinge region, suggesting that 
this region undergoes dynamic changes that were too subtle or occur on the a different 
timescale to have been detected in previous NMR experiments [50]. 
 
Figure 4.14 Regions identified to undergo significantly decreased HD exchange upon 
maltose binding of MBP. 
Significantly decreased regions shown in green. The structure is from PDB 1ANF. 
 
 
DEPC labeling of MBP results in 26 modified residues, yet only Lys297 shows a 
statistically significant decrease in labeling upon ligand binding (Figure 4.15). 
Unfortunately, of the seven modifiable residues (Lys15, Tyr17, His64, Tyr70, Lys326, 
Ser252, Thr356) in the four regions that undergo changes in HDX (i.e. 8-22, 62-76, 322-
336 and 346-361), none of them are found to be labeled by DEPC. The residue that does 
decrease in labeling, Lys297, is partially buried when the protein undergoes the 
conformational change from the open to closed state. This observation is also supported 
by the change in solvent accessible surface area (SASA) of Lys297 from 38% in the open 
state to 23% in the closed state. This decrease in SASA of Lys297 is the most significant 
decrease among all the measured DEPC modified residues upon ligand binding and the 
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conformational change (Table 4.3). A few residues become relatively more exposed upon 
ligand binding, such as Lys25 and Lys189, but these residues are already very exposed to 
solvent, and we have found that residues that are already highly exposed rarely undergo 
significant increases in labeling [38]. In other words, CL is more sensitive to decreases in 
SASA. 
 
Figure 4.15 Summary of CL result for MBP upon maltose binding. 
Summary of DEPC and HNSB labeling results for MBP upon maltose binding, and the 
location of modified residues mapped on the MBP-maltose complex structure (PDB ID 
1ANF). (1) Relative covalent labeling percentages with (red) and without (white) ligand 
bound. (2) Residues undergoing significant decreases in labeling are indicated in blue. 
Residues that are covalently labeled but undergo no significant change in labeling 
percentage are indicated in cyan.  
 
Because there are a limited number of residues along the maltose binding pocket 
that can be modified by DEPC, we applied another labeling reagent, HNSB, which 
specifically modifies tryptophan side chains with reaction kinetics that are similarly as 
slow as DEPC [23]. HNSB was chosen because there are two Trp residues (Trp230 and 
Trp340) near the binding site. Eight Trp residues are labeled by HNSB, and only Trp230 
and Trp340 significantly decrease in labeling extent upon ligand binding. It should be 
noted that Trp232, which is located near the hinge region also undergoes a notable 
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decrease in SASA (Table 4.3) but does not significantly decrease in labeling extent. The 
reasons for this are not clear.  
Comparing the results from HDX and CL for the MBP-maltose system further 
indicate the value of obtaining results from both techniques. The two methods together 
provide a clearer picture of the ligand binding site (Figure 4.16). CL data from both 
DEPC and HNSB reveal only residues that decrease in labeling due to significant 
decreases in SASA. Lys297, Trp230, and Trp340 all significantly decrease in SASA 
value upon ligand binding and the associated conformational change, but these three 
residues alone are somewhat insufficient to fully map the binding site. The data from 
HDX-MS alone is also insufficient to identify the binding site because too many non-
proximate regions of the protein undergo decreases in deuterium uptake in the presence 
of the ligand. Considering the data together, however, allows one to more confidently 
map the maltose binding site. 
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Table 4.3 SASA values of residues on MBP that are modified by DEPC or HNSB. 
Residue No ligand 
PDB 1OMP 
With ligand 
PDB 1ANF 
Residue No ligand 
PDB 1OMP 
With ligand 
PDB 1ANF 
K1 Not available in 
the structure 
Not available K179 62.3 68.9 
W10 11.9 10.6 K189 30.5 39.9 
K25 54.2 83.4 K200 67.2 62.2 
K26 67 64.7 K202 68.3 79.9 
W62 22.5 22.7 H203 15.7 16.4 
K83 96 94.1 W230 34.3 5.2 
K88 63.1 57.8 W232 10.3 1.2 
W94 3.8 3.6 K239 87.3 82.1 
K102 67.1 66.3 K251 48.6 56.6 
K119 48.3 47.1 K256 26.5 30.8 
K127 64.6 83.8 K273 43.7 44.7 
W129 0.3 1.1 K295 69.6 67.1 
K140 46.2 43.2 K297 38 23.9 
K142 62.5 48.5 K305 61.5 47 
K144 35.2 30.6 K313 87.8 71.7 
W158 0.1 1.4 W340 25 7.1 
 
 
Figure 4.16 A comparison of the differential CL and HDX results for the maltose 
binding protein mapped on its crystal structure. 
Regions that undergo significant decreases in HDX upon maltose binding are shown in 
green. Residues that undergo significant decreases in DEPC labeling are shown in blue. 
MBP crystal structure PDB 1ANF. 
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4.4 Conclusion 
Using three model protein-ligand systems, we demonstrate that HDX-MS and 
CL-MS can provide complementary and synergistic information about protein-ligand 
interactions. For brinzolamide binding to BCA and maltose binding to MBP, the two 
techniques together provide separate information that more clearly indicates the ligand 
binding site. Changes in side chain solvent accessibility upon ligand binding cause 
significant decreases in CL that complement the decreases in HDX that also occur at the 
ligand binding site. When used together on the same protein-ligand system, the different 
timescales of the two labeling techniques can also provide information that is not 
accessible to either technique alone. This synergy is most clearly evident in heme binding 
to myoglobin. Heme binding to myoglobin causes decreases in HDX at the ligand 
binding site and distant from the ligand binding site, which would make it difficult to 
definitively identify the heme binding site with HDX alone. In contrast, CL is only 
influenced by changes in side-chain solvent accessibility at the heme binding site and is 
insensitive to changes in protein structural fluctuations at sites distant from the heme 
binding site. When used together, HDX/MS and CL/MS provide more comprehensive 
information, revealing more clearly the binding site and ligand induced changes in 
protein structural fluctuations caused by the stabilizing effect of heme binding. With this 
better understanding of the complementarity and potential synergy of the two MS-based 
labeling techniques, we predict that these two methods will find widespread usage 
together for more deeply understanding protein-ligand systems that are important in areas 
such as drug discovery. 
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CHAPTER 5 
 
SUMMARY AND FUTURE DIRECTIONS 
5.1 Summary 
The work presented in this dissertation has focused on three main goals. First, we 
applied CL-MS for identifying ligand binding site on the protein. We studied two 
amyloid inhibiting molecules, doxycycline and rifamycin SV, identified their binding site 
on the Cu(II)-β2m monomer. Besides using DEPC, a labeling reagent which can modify 
6 kinds of amino acid side chains, BD labeling, which selectively modifies arginines, and 
the EDC/GEE labeling pair, which selectively modifies aspartic and glutamic acids, were 
also applied. Combining information from multiple kinds of labeling reagents increased 
the confidence in identifying ligand binding site. The determined doxycycline binding 
site on β2m is on the D β strand and rifamycin SV is between G β strand and D β strand. 
This result is distinct from that of suramin, which binds to Cu(II)-β2m, but is not an 
amyloid-inhibiting molecule. Suramin binds along the C β strand and near the C-D loop. 
More importantly, the conclusion is consistent with our group’s previous finding that 
doxycycline and rifamycin work by preventing β2m dimer to form tetramers. The work 
also suggests CL-MS could characterize protein-ligand complexes which aggregate fast 
and not capable to be studied by other methods such as X-ray crystallography.  
In the second goal, we inspected if slower CL reactions such as DEPC is capable 
to correctly determine the Kd of the protein-ligand complexes. It is usually considered 
that due to the slow intrinsic reaction rate, non-radical CL reactions will distort the 
equilibrium of protein-ligand towards dissociation side, thus they cannot correctly 
determine the Kd. However, experiment results of two model systems: (NAG)3-lysozyme 
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and maltose-maltose binding protein suggested as long as a proper strategy being applied, 
these CL methods are capable to correctly determine the Kd. The Kd we measured were 
not significantly off from what being acquired by other methods such as fluorescence and 
ESI-MS. We also discussed the key condition that the experiment design should follow, 
which is the fraction of protein that get labeled at the ligand binding site in the system 
must be limited at a low rage (e.g. below 30%). If large fraction (e.g. more than 50%) of 
protein are labeled at the ligand binding site, acquired Kd would be significantly off from 
the actual value. We also applied the developed strategy to a system with an unknown Kd: 
EGCG and Cu(II)-β2M. Besides successfully determined Kd values using residue level 
labeling results from two different residues, we also identified EGCG binding site of 
Cu(II)-β2M monomer. 
  The third goal of this dissertation work was to compare the information from 
two complementary MS based methods, HDX-MS and CL-MS, when they are each 
applied to characterize the same protein-ligand complex. The intrinsic reaction rate of the 
two methods are 2-3 orders of magnitude difference. We expect CL, which rate is at 10’s 
of second level, will be insensitive to ligand binding induced dynamic change to the 
protein. While HDX is known able to measure the dynamic change as well as protection 
brought by ligand binding, CL might help distinguish remote dynamic changes from 
protection due to decreased solvent accessibility.  To examine our idea, we inspected 
three well-characterized model systems.  
In the first model system, heme binding can significantly stabilize apomyoglobin. 
We observed near 70% of the myoglobin sequence decrease in deuterium uptake by 
HDX, while CL pinpointed 13 residues surrounding heme binding pocket. CL helped 
  130 
distinguish dynamic change region from ligand binding site. In the second model system, 
bovine carbonic anhydrase II is a rigid protein that does not undergo dynamic or 
conformational change upon brinzolamide binding. While CL can easily identify ligand 
binding site with solvent exposure decrease of His63 caused by ligand binding. HDX 
only indicated limited decreases in exchange even for up to 24 h of exchange, likely due 
to the rigidity of the protein. The third model we inspected was maltose and maltose 
binding protein. Maltose binding protein will undergo significant conformational change 
upon maltose binding. Again, experiment result indicated CL is sensitive to changes in 
side chain’s solvent accessibility. Overall, our experiment results lead us to the 
conclusion that due to its slower intrinsic reaction rate, some CL methods are insensitive 
to protein’s dynamic changes. Thus, CL can help distinguish remote changes in protein 
dynamics from protections caused by ligand binding. Synergistic structural information 
available if CL-MS and HDX-MS are used to characterize protein-ligand complexes.  
This dissertation highlights the power of CL-MS to characterize protein-ligand 
complexes. Our work has demonstrated that CL-MS can identify ligand binding site of 
the protein, determine the binding affinity of ligand to the protein, and indicate some 
major conformational change of the protein induced by ligand binding. If combine the 
information of CL-MS with HDX-MS synergistic information will allow a more 
comprehensive understanding of ligand binding sites and ligand induced structural 
changes, which can greatly assist drug discovery and related procedures. The study of 
several amyloid inhibiting molecules to Cu(II)-β2M also partially explained the 
mechanism of these inhibitors. Determined inhibitor binding site of Cu(II)-β2m could 
facilitate future library screening of new drug candidates. Our work also demonstrated 
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that CL-MS could characterize protein-ligand complexes that aggregate fast. This 
technique could be applied to study proteins that are not capable to be by other methods 
such as X-ray crystallography and nuclear magnetic resonance spectroscopy (NMR). 
5.2 Limitation of the Method 
While we demonstrated that CL-MS can be useful for characterizing protein-
ligand complexes, it does have some limitations that could be overcome with future 
research. First, a ligand binding site and nearby region must consist of CL modifiable 
residues to obtain binding site information. Through the study of several model systems 
as discussed in this thesis, we see that His and Lys, which are two of the most reactive 
residues for DEPC, are often not present within a ligand binding site. Although in a few 
cases a His or Lys can be found close enough to the ligand binding site and able to 
provide some information about ligand binding. While Ser, Tyr, or Thr can also be DEPC 
labeled, they seems less informative as there is no case that a ligand binding site is 
determined just by their labeling result. In Chapter 2, we discussed that additional 
information from one or more other kinds of labeling reagents that could help improve 
the overall confidence in the conclusion. However, suppose one is trying to determine the 
ligand binding site to a protein with no prior information available, starting with DEPC or 
residue specific labeling reagents likely will require multiple measurements to obtain the 
binding site information.  
Also, by the nature of the strategy, information is only available from residues 
that are CL modified. For the rest of the sequence that is not CL covered, no information 
available from the method. Depending on the situation, a cluster of such CL unmodified 
residues with no information could be large enough to miss out the ligand binding site or 
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structural changes. Or, such a cluster could decrease the overall reliability of the 
conclusion for the ligand binding site.  
To minimize the limitations discussed above, new CL reagents which can modify 
more kinds of residues could help. Clearly, the more kinds of residues being modified, 
the higher the sequence coverage will be and less likely an area be missed out by the 
method. A new CL reagent is preferred to have a similar reaction rate to the CL reactions 
used in this thesis in order to transfer the developed strategies. One example is a series of 
new CL reagents being explored in our lab, that use α, β-unsaturated carbonyl compounds 
that can react with 13 kinds of residues.    
Second, a structure of the protein is preferred to assist the data interpretation. As 
used many times in this thesis, a structure of the protein assists the final steps of 
interpreting the result from CL-MC, facilitate comparison of the spatial distribution of 
CL modified residues. Without the spatial distribution relationship, the result of CL will 
be much less meaningful, as very likely one cannot decide if CL significantly changed 
residues are focused as one cluster or not. Although all the proteins applied in this thesis 
have at least one available structure, it may not be required if effective molecular 
modeling could be done. The computational modeling here especially refers to the 
modeling strategy that use covalent labeling data to determine protein structure and 
interactions [1-5]. For example, Chance and co-workers have developed the ClusPro 
program for predicting protein complexes using the restraints from hydroxyl radical 
labeling to facilitate homology modeling and associated protein structural prediction for 
protein complexes with no NMR or X-ray crystal structure [2]. Similar work that uses 
DEPC labeling is being investigated in our lab. 
  133 
 
5.3 Future Directions 
5.3.1 CL-MS and Protein-Ligand Docking for Screening New β2m Amyloid 
Inhibiting Molecules 
In the work described in Chapter 2, we applied computational protein-ligand 
docking. Docking refined the structural information acquired by CL-MS and confirmed 
the experimental determined ligand binding site. While the way we applied docking is 
one of the options, in industry, using protein-ligand docking to screen possible 
interactions between thousands of compound to the target protein is a routine [6-8]. 
Comparing to experimental methods, docking is high throughput that can inspect 
thousands of compounds within a short time at low cost. However, docking cannot stand 
alone. Docking identified candidates still need to be verified by experiments before they 
are subjected to further studies [7]. 
In Chapters 2 and 3, we studied the binding site of doxycycline, rifamycin SV, 
and EGCG to Cu(II)-β2m monomer. This information could instruct docking process for 
screening new β2m amyloid inhibiting molecules, by specifying region(s) that the 
candidates should bind to. For example, EGCG binding is likely among N-terminus of 
the protein and EGCG induced Cu(II) binding to the protein become weaker. New 
inhibitor candidate could bind in a similar manner but with a much stronger binding 
affinity to β2m. Once the candidates are reported by docking, experimental methods 
including CL-MS can again be applied to confirm the binding site of the protein as 
described in Chapter 2. The final candidates could then be incubated with β2m for further 
studies. 
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5.3.2 Distinguish Conformational Change from Ligand Binding Site in a CL-MS for 
Characterizing Protein-Ligand Complexes Experiment 
As described in Chapters 3 and 4, our experiment results indicate CL-MS can also 
identify regions that undergo significant conformational changes upon ligand binding. 
Residues from such region will have changes in solvent accessibility, which can be 
reflected by residue level labeling ratio.  However, as identifying ligand binding site also 
relies on decreases in solvent accessibility, it might be difficult to assign whether the 
labeling decrease is due to conformational changes or ligand binding. For example, in 
maltose binding protein, Lys297 significantly decreased in labeling ratio. Without a prior 
understanding of Lys297 get buried in during the conformational change, we might 
misassign the labeling decrease is due to ligand binding.  
While applying HDX-MS, as described in Chapter 4, could help solve this 
potential problem. We hypothesize that inspecting the relative decreases of CL ratio 
might also help distinguish protein conformational changes from the ligand binding site. 
The decrease in residue’s solvent accessibility induced by conformational change might 
not be as significant as ligand binding induced decrease. As a result, it might be 
reasonable to expect a residue directly involved in ligand binding has a relatively larger 
fractional decrease in labeling ratio, comparing to a residue from the conformational 
change region. At the same time, residues with increased labeling ratio could also help 
solve the problem. In a simple assumption, an allosteric site is more likely to have a 
residue become more solvent exposed during the transformation of the protein, 
comparing to the ligand binding site. Or, the relative fractional increase in labeling will 
be different enough to help distinguish the origin of two increased residues, with the 
increase in an allosteric site being larger. Model proteins which have multiple residues 
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significantly changes in labeling from both ligand binding site and conformational 
change region could verify this idea. 
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